<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Prevention of venous thromboembolic disease in acutely ill hospitalized medical adults</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Prevention of venous thromboembolic disease in acutely ill hospitalized medical adults</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Prevention of venous thromboembolic disease in acutely ill hospitalized medical adults</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">James D Douketis, MD, FRCPC, FACP, FCCP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Siraj Mithoowani, MD, MHPE, FRCPC</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jess Mandel, MD, MACP, ATSF, FRCP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David A Garcia, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Geraldine Finlay, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 06, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>It is estimated that over half of hospitalized medical patients are at risk for venous thromboembolism (VTE; ie, deep vein thrombosis and/or pulmonary embolus) [<a href="#rid1">1</a>]. In addition, it is widely believed that PE is the most common preventable cause of hospital death [<a href="#rid2">2-8</a>].</p><p>This topic review discusses the prevention of VTE in patients hospitalized for acute medical illnesses [<a href="#rid9">9</a>]. Approaches to the prevention of VTE in surgical patients and patients with cancer and stroke, as well as in pregnancy are presented separately. (See  <a class="medical medical_review" href="/z/d/html/1339.html" rel="external">"Prevention of venous thromboembolic disease in adult nonorthopedic surgical patients"</a> and  <a class="medical medical_review" href="/z/d/html/1352.html" rel="external">"Risk and prevention of venous thromboembolism in adults with cancer"</a> and  <a class="medical medical_review" href="/z/d/html/1347.html" rel="external">"Venous thromboembolism in pregnancy: Prevention"</a> and  <a class="medical medical_review" href="/z/d/html/121857.html" rel="external">"Prevention and treatment of venous thromboembolism in patients with acute stroke", section on 'Approach to VTE prevention'</a>.)</p><p class="headingAnchor" id="H4"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>While many epidemiologic studies report venous thromboembolism (VTE) rates, in the absence of prophylaxis, that range from 10 to 80 percent, these rates are likely overestimated [<a href="#rid2">2,3,5,10-26</a>].</p><p>Accurate estimates of the incidence of clinically meaningful venous thromboembolic disease (ie, pulmonary embolus [PE] and deep vein thrombosis [DVT]) in hospitalized medical patients have been hampered by factors including the derivation of data from mixed surgical and medical populations, the reporting of both symptomatic and asymptomatic events, the increasing use of thromboprophylaxis and early ambulation during hospital admission, and the trend toward reducing length of hospital stay.</p><p>Thromboprophylaxis has been shown to reduce the risk of VTE in hospitalized medical and surgical patients. While thromboprophylaxis has been reported to reduce the risk of death in surgical patients [<a href="#rid27">27,28</a>], most studies and a meta-analysis have not been able to show a consistent beneficial effect of thromboprophylaxis on mortality in hospitalized medical patients [<a href="#rid29">29-37</a>]. The reasons for this difference between medical and surgical patients are unclear but may be related to a greater number of comorbidities in medical patients that contribute to overall deaths. In addition, the baseline risk in medical patients is lower than in surgical patients, and therefore, most studies or meta-analyses may be underpowered to demonstrate an effect of thromboprophylaxis in mortality [<a href="#rid38">38</a>]. Finally, clinicians should be aware that VTE prophylaxis does not eliminate the risk of VTE or VTE-related death in hospitalized patients.</p><p>The risk of VTE in specific medical populations is discussed in this section, while the effect of thromboprophylaxis in these groups is described below. (See <a class="local">'Methods of thromboprophylaxis'</a> below.)</p><p class="headingAnchor" id="H8"><span class="h2">General medical patients</span><span class="headingEndMark"> — </span>Compared with the community, most patients admitted with an acute medical illness are at increased risk for VTE during and following hospital admission [<a href="#rid2">2,3,5,26,39</a>]. One retrospective medical record review of 911 patients with VTE reported that the age- and sex-adjusted incidence of VTE was more than 130 times greater among hospitalized patients than among community residents with 60 percent of all cases occurring in hospitalized, recently discharged, or nursing home patients [<a href="#rid26">26</a>]. Older age and male sex appeared to be risk factors for the development of in-hospital VTE. Other studies have reported that PE is responsible for death in up to one-third of hospitalized medical patients and 45 percent of VTE events occurs in the three months following discharge, although some of these figures may be an over estimate based upon interpretation of autopsy results [<a href="#rid2">2,3,5,39</a>].</p><p class="headingAnchor" id="H1842897653"><span class="h2">High-risk populations</span><span class="headingEndMark"> — </span>Compared with other patient groups, the groups of medical patients listed below are at particularly high risk for the development of VTE during hospital admission or after discharge.</p><p class="headingAnchor" id="H8747283"><span class="h3">Intensive care unit patients</span><span class="headingEndMark"> — </span>All patients admitted to intensive care units (ICUs) are considered high risk for VTE (both upper and lower extremity venous thrombosis; approximately 10 percent), even after routine prophylactic anticoagulation [<a href="#rid21">21,40-45</a>]. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>A retrospective study of over 150,000 critically ill adults reported mortality was higher in those who received delayed thromboprophylaxis (ie, within the first 24 hours) compared with those who received prophylaxis from the time of admission (8 versus 6 percent [ICU mortality] and 11 versus 10 percent [hospital mortality]). [<a href="#rid46">46</a>]. The increase in mortality attributed to delayed thromboprophylaxis varied depending upon the population, and was reported as 4 percent (trauma patients), 8 percent (sepsis patients), 9 percent (cancer patients), and 15 percent (patients who survived a cardiac arrest). (See  <a class="medical medical_review" href="/z/d/html/7956.html" rel="external">"Overview of inpatient management of the adult trauma patient", section on 'Thromboprophylaxis'</a> and  <a class="medical medical_review" href="/z/d/html/113028.html" rel="external">"Venous thromboembolism risk and prevention in the severely injured trauma patient", section on 'Thromboprophylaxis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a post-hoc analysis of a randomized trial of 3746 critically ill patients, the incidence of VTE was 8 percent (5 percent DVT, 2 percent PE, 1 percent DVT plus PE) [<a href="#rid45">45</a>]. Predictors of thromboprophylaxis failure included a personal or family history of VTE and obesity).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a retrospective analysis of 678 ICU patients, 5 percent had DVT despite being on thromboprophylaxis. A history of DVT was the strongest predictor for the development of proximal DVT [<a href="#rid47">47</a>].</p><p></p><p class="headingAnchor" id="H1842897673"><span class="h3">Cancer</span><span class="headingEndMark"> — </span>VTE is a common complication in patients with active malignancy, defined as cancer in the advanced stages or for which patients are receiving antineoplastic treatment. Detailed discussion of the risk of VTE in patients with active malignancy is provided separately. (See  <a class="medical medical_review" href="/z/d/html/1352.html" rel="external">"Risk and prevention of venous thromboembolism in adults with cancer"</a>.)</p><p class="headingAnchor" id="H1842897679"><span class="h3">Stroke</span><span class="headingEndMark"> — </span>VTE is a common complication of stroke, particularly in those with lower limb paralysis. Detailed discussion of the risk of VTE in patients with stroke is provided separately. (See  <a class="medical medical_review" href="/z/d/html/121857.html" rel="external">"Prevention and treatment of venous thromboembolism in patients with acute stroke"</a>.)</p><p class="headingAnchor" id="H1842897693"><span class="h3">Other</span><span class="headingEndMark"> — </span>Pregnancy is a risk factor for VTE. Detailed discussion of the overall risk of VTE during pregnancy as well as risk in pregnant women admitted to hospital are provided separately. (See  <a class="medical medical_review" href="/z/d/html/1349.html" rel="external">"Deep vein thrombosis in pregnancy: Epidemiology, pathogenesis, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/1347.html" rel="external">"Venous thromboembolism in pregnancy: Prevention", section on 'Inpatient thromboprophylaxis'</a>.)</p><p>There are numerous additional risk factors for VTE that may be present in hospitalized medical patients including heart failure, myocardial infarction, and age &gt;60 years, as well as previous VTE, prolonged immobility, renal failure, obesity, inherited or acquired hypercoagulable states, and coronavirus disease 2019 (COVID-19). These and other causes of VTE are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1361.html" rel="external">"Overview of the causes of venous thrombosis"</a> and  <a class="medical medical_review" href="/z/d/html/127926.html" rel="external">"COVID-19: Hypercoagulability"</a>.)</p><p class="headingAnchor" id="H2349552413"><span class="h2">Effect of statin or aspirin on risk</span><span class="headingEndMark"> — </span>We believe that the nature of the acute illness dictates the overall risk of VTE such that the approach to patients on statins and <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> should be no different to that in general medical or high-risk populations, and that statins or aspirin should not be used as thromboprophylaxis agents. Despite studies that suggest a lower risk of VTE in nonhospitalized patients on statins and aspirin, several trials did not show benefit to the baseline risk of VTE. Conflicting outcomes may be due to the impact of variables common in patients taking statins or aspirin that may concurrently increase or decrease the risk of VTE (eg, age, ischemic heart disease, other antiplatelet agents).</p><p>Data that report the risk of VTE associated with statin and <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> use in the general population are described below:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Statins</strong> – Several studies including randomized trials, national database registries, population cohorts, and meta-analyses have reported conflicting effects of statins on the prevention of VTE [<a href="#rid48">48-59</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In the JUPITER trial, 17,802 healthy adults with marginal elevations in cholesterol were randomly assigned to treatment with oral <a class="drug drug_general" data-topicid="10282" href="/z/d/drug information/10282.html" rel="external">rosuvastatin</a> (20 mg/day) or placebo [<a href="#rid49">49</a>]. Compared with placebo, rosuvastatin was associated with a reduction in the rate of symptomatic VTE (0.18 versus 0.32 events/100 person-years). Subgroup analysis showed similar decreases in the rates of deep venous thrombosis and pulmonary embolism, regardless of whether the event was provoked or unprovoked.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>One meta-analysis of 29 randomized clinical trials that included patients from JUPITER reported that statin therapy did not significantly reduce the risk of VTE events (odds ratio [OR] 0.89, 95% CI 0.78-1.01) [<a href="#rid60">60</a>]. Compared with standard dose therapy, the same lack of benefit was reported in patients taking high-dose statin regimens (OR 0.98, 95% CI 0.8-1.2).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">Aspirin</a> – Most epidemiologic studies suggest that aspirin in healthy individuals does not reduce the risk of VTE. As examples:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In the Women's Health Study, VTE rates were no different in healthy females that were randomly assigned to receive either low-dose <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> (100 mg orally every other day) or placebo for 10 years (1.18 versus 1.25 events per 1000 patient-years) [<a href="#rid61">61</a>]. On subgroup analysis, no VTE risk factor (ie, age, obesity, menopausal status, reported VTE at baseline, factor V Leiden, prothrombin gene mutation) modified the relationship between aspirin and the overall risk of VTE. However, the use of aspirin was associated with an increased risk of gastrointestinal bleeding, peptic ulcer, hematuria, bruising, and epistaxis.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a population-based case-control study, an analysis restricted to individuals without a history of cardiovascular events indicated that the current use of <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> did not significantly reduce the incidence of VTE [<a href="#rid48">48</a>].</p><p></p><p class="headingAnchor" id="H1842901614"><span class="h1">DEFINITION OF VTE PROPHYLAXIS</span><span class="headingEndMark"> — </span>Prevention of venous thromboembolism (VTE) can be defined as primary or secondary. Primary thromboprophylaxis is preferred because its efficacy is well established and it is more cost effective than treatment of complications once they occur [<a href="#rid62">62</a>].</p><p class="headingAnchor" id="H1842903009"><span class="h2">Primary prophylaxis</span><span class="headingEndMark"> — </span>Primary prophylaxis, the preferred method for VTE prevention, is carried out using either drugs (eg, heparin) or mechanical methods (eg, intermittent pneumatic compression boots) that are effective for preventing deep vein thrombosis (DVT). The characteristics of an ideal primary prophylactic method include ease of administration, effectiveness, safety (particularly with respect to bleeding), and cost-effectiveness or at least cost-neutrality. The prophylactic measures available for hospitalized medical patients include low-dose <a class="drug drug_general" data-topicid="8518" href="/z/d/drug information/8518.html" rel="external">unfractionated heparin</a>; low molecular weight (LMW) heparins; <a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">fondaparinux</a>; intermittent pneumatic compression (IPC) and/or graduated compression stockings (GCS) [<a href="#rid63">63</a>]; and where available, oral factor Xa or direct thrombin inhibitors. (See  <a class="medical medical_review" href="/z/d/html/1370.html" rel="external">"Direct oral anticoagulants (DOACs) and parenteral direct-acting anticoagulants: Dosing and adverse effects", section on 'Direct thrombin inhibitors'</a> and  <a class="medical medical_review" href="/z/d/html/1370.html" rel="external">"Direct oral anticoagulants (DOACs) and parenteral direct-acting anticoagulants: Dosing and adverse effects", section on 'Direct factor Xa inhibitors'</a> and  <a class="medical medical_review" href="/z/d/html/1348.html" rel="external">"Heparin and LMW heparin: Dosing and adverse effects"</a> and  <a class="medical medical_review" href="/z/d/html/1319.html" rel="external">"Fondaparinux: Dosing and adverse effects"</a> and  <a class="medical medical_review" href="/z/d/html/1335.html" rel="external">"Prevention of venous thromboembolism in adults undergoing hip fracture repair or hip or knee replacement"</a>.)</p><p class="headingAnchor" id="H1842903015"><span class="h2">Secondary prophylaxis</span><span class="headingEndMark"> — </span>Secondary prevention involves the early detection and treatment of subclinical venous thrombosis by screening medical patients with objective tests that are sensitive for the presence of DVT. However, the benefits of available screening methods (eg, venous ultrasound, magnetic resonance imaging venography) on patient important outcomes is not well-established [<a href="#rid64">64,65</a>]. Accordingly, secondary prevention is often reserved for patients in whom primary prophylaxis is either contraindicated or shown to be ineffective. Secondary prophylaxis is also used during pregnancy in women with a high clinical suspicion for DVT but a negative compressive lower extremity ultrasound, the details of which are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1349.html" rel="external">"Deep vein thrombosis in pregnancy: Epidemiology, pathogenesis, and diagnosis"</a>.)</p><p class="headingAnchor" id="H10"><span class="h1">OUR APPROACH</span><span class="headingEndMark"> — </span>Our approach is, for the most part, consistent with guidelines issued by several societies including the American College of Chest Physicians, the Neurocritical Care Society, the Society of Critical Care Medicine, and the American Society of Hematology [<a href="#rid66">66-69</a>].</p><p class="headingAnchor" id="H5138262"><span class="h2">Assess risk</span></p><p class="headingAnchor" id="H1842910815"><span class="h3">Thrombosis risk assessment</span><span class="headingEndMark"> — </span>The risk of venous thromboembolism (VTE) depends upon the nature of the acute illness and the presence of individual risk factors. A full history and examination should be obtained to assess this risk in all acutely ill hospitalized medical patients. We consider that medical patients admitted to hospital with at least one risk factor for VTE are at risk for the development of deep venous thrombosis and/or pulmonary embolism (PE). Risk factors commonly encountered in patients admitted to hospital include heart failure, acute respiratory failure (eg, acute exacerbations of chronic pulmonary disease), sepsis, inflammatory bowel disease, known thrombophilia, prolonged immobility ≥3 days, age &gt;60 years, previous VTE, those with multiple risk factors, and possibly patients with an elevated D-dimer [<a href="#rid19">19,29,38-41,63,70-83</a>]. In addition, patients at particularly high risk of VTE include those who are critically ill, patients with lower limb paralysis from stroke, and patients with active cancer. (See  <a class="medical medical_review" href="/z/d/html/1361.html" rel="external">"Overview of the causes of venous thrombosis"</a> and <a class="local">'High-risk populations'</a> above.)</p><p>Most clinicians empirically assess risk and administer thromboprophylaxis based upon this assessment (see <a class="local">'Selection of method of prophylaxis'</a> below). However, a number of empirically generated or data-derived risk models, based upon a number of the above-noted risk factors have been proposed [<a href="#rid84">84</a>]. These prediction scores require further validation from independent, prospective studies before they can be used in routine practice [<a href="#rid85">85</a>] but are described in brief below:</p><p class="bulletIndent1"><span class="glyph">●</span>The <strong>Padua Prediction Score</strong> was used to determine VTE risk in 1180 consecutive medical patients. Patients were followed for up to 90 days following admission to assess the occurrence of symptomatic VTE [<a href="#rid86">86,87</a>]. The rate of VTE was as follows (<a class="calc calc_professional" href="/z/d/html/103133.html" rel="external">calculator 1</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Low-risk patients (score &lt;4): 0.3 percent</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>High-risk patients (score ≥4): 2.2 (receiving adequate in-hospital thromboprophylaxis) and 11 percent (not receiving adequate in-hospital thromboprophylaxis)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The <strong>IMPROVE risk score</strong> was used to determine VTE risk in 15,156 medical patients enrolled in the observational International Medical Prevention Registry on Venous Thromboembolism (IMPROVE) study [<a href="#rid39">39</a>]. The observed rate of VTE within 92 days of admission was 0.4 to 0.5 percent if none of four risk factors was present (prior VTE, active cancer, age &gt;60 years, and thrombophilia), and was in the range of 8 to 11 percent in those with the highest risk scores (three to four factors present) (<a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.outcomes-umassmed.org%2FIMPROVE%2Frisk_score%2Fvte%2Findex.html&amp;token=erEtv2h4SKbehy52hBNFQ4C8qBxX5%2BoV2yJv4xO%2BcQtRY1Y54y4ncgICblrBqOR%2FdN0a%2FSHjcPnS%2F6hXVu6U7WsoYwKg9fAVkdhlslzSSMc%3D&amp;TOPIC_ID=1346" target="_blank">IMPROVE thrombosis risk model</a>).</p><p></p><p class="bulletIndent1">A modified IMPROVE risk score incorporates a D-dimer level, measured during hospitalization, in which a score of 2 or 3 plus a D-dimer greater than twice the upper limit of normal identifies patients at increased risk for symptomatic VTE [<a href="#rid88">88,89</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A score of 0 or 1 identifies patients with a risk for VTE of 0.4 to 0.6 percent at 42 days and a risk of 0.5 to 0.7 percent at 77 days.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A score of 2 or 3 (considered high risk) identifies patients with a risk for VTE of 0.8 to 1 percent at 42 days and a risk of 1 to 1.2 percent at 77 days.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A score of 4 or 5 identifies patients with a risk for VTE of 1.6 to 1.9 percent at 42 days and a risk of 2.2 to 2.7 percent at 77 days.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A score of 6 or 7 has a similar risk for VTE as a score of 4 or 5.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The <strong>GENEVA risk score</strong> was tested in a multicenter validation study that included 1478 hospitalized medical patients, 43 percent of whom did not receive thromboprophylaxis [<a href="#rid19">19,90</a>]. The risk of symptomatic VTE or VTE-related death at 90 days was the following (<a class="calc calc_professional" href="/z/d/html/103134.html" rel="external">calculator 2</a>) [<a href="#rid90">90</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Low-risk patients (score &lt;3): 0.6 percent (receiving adequate in-hospital thromboprophylaxis) and 0.8 percent (not receiving adequate in-hospital thromboprophylaxis.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>High-risk patients (score ≥3): 3.2 percent (receiving adequate in-hospital thromboprophylaxis) and 3.5 percent (not receiving adequate in-hospital thromboprophylaxis).</p><p></p><p class="headingAnchor" id="H1940969149"><span class="h3">Bleeding risk assessment</span><span class="headingEndMark"> — </span>A full history and examination should be obtained to assess the risk of bleeding in all acutely ill hospitalized medical patients in whom pharmacologic VTE prophylaxis is warranted. Examples of medical patients at high risk of bleeding in whom pharmacologic thromboprophylaxis is typically contraindicated, include those with active bleeding or intracranial hemorrhage, those in whom a surgical procedure is planned in the immediate 6 to 12 hours (eg, spinal neuroaxial anesthesia), patients who have a moderate or severe coagulopathy, and patients with a severe bleeding diathesis or thrombocytopenia (eg, platelet count &lt;50,000/microL or &lt;100,000/microL plus additional risk factors for bleeding). Epistaxis and menstrual bleeding are not contraindications to pharmacologic thromboprophylaxis.</p><p>Validated models for evaluating the risk of bleeding in hospitalized medical patients are lacking [<a href="#rid91">91,92</a>]. Retrospective analysis of data from the International Medical Prevention Registry on Venous Thromboembolism (IMPROVE) has been used to assess in-hospital bleeding incidence in 15,156 medical patients and to identify risk factors at the time of admission associated with in-hospital bleeding risk [<a href="#rid91">91</a>]. The cumulative incidence of major and nonmajor in-hospital bleeding within 14 days of admission was 3.2 percent. The strongest independent risk factors for bleeding at the time of admission were the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Active gastroduodenal ulcer (odds ratio [OR] 4.15, 95% CI 2.21-7.77)</p><p class="bulletIndent1"><span class="glyph">●</span>Bleeding within the three months prior to admission (OR 3.64, 95% CI 2.21-5.99)</p><p class="bulletIndent1"><span class="glyph">●</span>Platelet count &lt;50,000/microL (OR 3.37, 95% CI 1.84-6.18)</p><p></p><p>Other bleeding risk factors included increased age, hepatic and/or renal failure, intensive care unit stay, presence of a central venous catheter, rheumatic disease, cancer, and male sex (ie, factors that also increase the risk of VTE). Each of the above risk factors, with appropriate weighting, was entered into a risk model (<a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.outcomes-umassmed.org%2FIMPROVE%2Frisk_score%2Fbleeding%2Findex.html&amp;token=jTKjdgVzsoYLR7Hjd7Upg%2FZDilQ5AuiF%2BXoj8LFnCEbpm25RqqtgSxZ1YPvVkKLVHz0lauRUL3t9m2DnWP5kONADSCzU2FvHVge0C1%2BdHkU%3D&amp;TOPIC_ID=1346" target="_blank">IMPROVE Bleeding risk model</a>) with scores ranging from 0 to 15. Overall rates of bleeding were the following in patients with:</p><p class="bulletIndent1"><span class="glyph">●</span>Risk scores of 1: 0.5 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Risk scores of 4: 1.6 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Risk scores of 7: 4.1 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Risk scores of 15: 14 percent</p><p></p><p>Further validation of this model is warranted before it can be routinely used to assist clinicians in estimating the risks of bleeding from pharmacologic thromboprophylaxis in patients at risk for VTE.</p><p class="headingAnchor" id="H5137695"><span class="h2">Selection of method of prophylaxis</span><span class="headingEndMark"> — </span>Selecting a method of thromboprophylaxis is dependent upon many factors including the nature of the acute medical illness, the risk of hemorrhage and thrombosis, preferences and values of the patient, institutional policy, and cost. Although thromboprophylaxis is typically individualized, our approach in hospitalized medical patients is outlined in the sections below. These suggestions apply to hospitalized medical patients regardless of whether or not they are receiving <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> or statins on admission. (See <a class="local">'Effect of statin or aspirin on risk'</a> above.)</p><p class="headingAnchor" id="H20641627"><span class="h3">Low-risk patients</span><span class="headingEndMark"> — </span>For most patients hospitalized with an acute medical illness and who are without obvious risk factors for VTE (eg, young patients admitted for a 12 hour observation following an episode of syncope from hypoglycemia), pharmacologic thromboprophylaxis is <strong>not</strong> warranted. Options for this low-risk group include early ambulation with or without mechanical methods of thromboprophylaxis. (See <a class="local">'Mechanical methods of thromboprophylaxis'</a> below.)</p><p class="headingAnchor" id="H20641633"><span class="h3">Moderate-risk patients</span><span class="headingEndMark"> — </span>For most patients hospitalized with an acute medical illness, who have at least one risk factor for VTE and do not have an increased risk of bleeding, we recommend the use of pharmacologic thromboprophylaxis rather than mechanical methods or no prophylaxis. Low molecular weight (LMW) heparin is generally the preferred anticoagulant based upon randomized trials that suggest it is superior for preventing deep vein thrombosis (DVT). For those with renal failure (creatinine clearance &lt;30 mL/min) or for those in whom cost is an issue, <a class="drug drug_general" data-topicid="8518" href="/z/d/drug information/8518.html" rel="external">unfractionated heparin</a> (UFH) is a reasonable alternative to LMW heparin. (See <a class="local">'Pharmacologic thromboprophylaxis'</a> below.)</p><p class="headingAnchor" id="H20641639"><span class="h3">High-risk patients</span><span class="headingEndMark"> — </span>For most patients hospitalized with an acute medical illness who are considered to be at high risk for VTE (eg, critically ill, cancer, stroke) and at low risk of bleeding, we recommend the use of pharmacologic thromboprophylaxis rather than mechanical methods or no prophylaxis. In general, we prefer LMW heparin rather than other anticoagulants but UFH is an alternative in those with renal failure or in whom cost is an issue. (See <a class="local">'Pharmacologic thromboprophylaxis'</a> below.)</p><p class="headingAnchor" id="H20641667"><span class="h3">Special populations</span></p><p class="headingAnchor" id="H101169326"><span class="h4">Heparin-induced thrombocytopenia</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">Fondaparinux</a> may be used as an alternative to heparin in patients with a history of heparin-induced thrombocytopenia. (See <a class="local">'Pharmacologic thromboprophylaxis'</a> below and  <a class="medical medical_review" href="/z/d/html/1369.html" rel="external">"Management of heparin-induced thrombocytopenia"</a>.)</p><p class="headingAnchor" id="H20641730"><span class="h4">At risk of bleeding</span><span class="headingEndMark"> — </span>For most patients hospitalized with an acute medical illness who have risk factors for VTE and who are at high risk of bleeding or in whom anticoagulation is contraindicated (eg, gastrointestinal or intracranial hemorrhage), mechanical methods of VTE prevention (eg, intermittent pneumatic compression, graduated compression stockings, venous foot pump) are suggested over no prophylaxis [<a href="#rid66">66</a>]. Among these methods, pneumatic compression devices and graduated compression stockings are the most common forms of mechanical prophylaxis used. When mechanical forms of prophylaxis are used, transition to a pharmacologic agent should occur as soon as the bleeding risk becomes acceptably low (eg, often within 24 to 48 hours) or has been reversed [<a href="#rid66">66</a>]. (See <a class="local">'Mechanical methods of thromboprophylaxis'</a> below.)</p><p class="headingAnchor" id="H20641784"><span class="h4">Other</span><span class="headingEndMark"> — </span>Special populations of medical patients require an individualized approach to thromboprophylaxis during an acute hospitalization. Detailed discussion of those populations is provided separately:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients undergoing neuraxial anaesthesia or analgesia (see  <a class="medical medical_review" href="/z/d/html/14930.html" rel="external">"Neuraxial anesthesia/analgesia techniques in the patient receiving anticoagulant or antiplatelet medication"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with stroke (see  <a class="medical medical_review" href="/z/d/html/121857.html" rel="external">"Prevention and treatment of venous thromboembolism in patients with acute stroke"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients who are pregnant (see  <a class="medical medical_review" href="/z/d/html/1347.html" rel="external">"Venous thromboembolism in pregnancy: Prevention"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with cancer (see  <a class="medical medical_review" href="/z/d/html/1352.html" rel="external">"Risk and prevention of venous thromboembolism in adults with cancer"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients traveling for extended periods (see  <a class="medical medical_review" href="/z/d/html/101332.html" rel="external">"Prevention of venous thromboembolism in adult travelers"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with spinal cord injury (see  <a class="medical medical_review" href="/z/d/html/5120.html" rel="external">"Respiratory complications in the adult patient with chronic spinal cord injury", section on 'Venous thromboembolism'</a>)</p><p></p><p class="headingAnchor" id="H5137702"><span class="h2">Duration of prophylaxis</span><span class="headingEndMark"> — </span>VTE prophylaxis should ideally continue until the patient is fully ambulatory or discharged from the hospital. Although data do not support routinely extending the duration of thromboprophylaxis in acutely ill medical patients beyond admission, in our experience select populations should probably receive extended thromboprophylaxis (eg, nonambulatory patients, patients unable to ambulate independently or mechanically ventilated patients admitted to acute rehabilitation for physical therapy or ventilator weaning). Thromboprophylaxis is typically not administered in chronically immobilized patients residing at home or in a nursing home [<a href="#rid66">66</a>]. The optimal degree of ambulation that provides protection or reduced risk for DVT is unknown.</p><p>Although extended duration prophylaxis (ie, beyond the acute hospital stay), has been shown to benefit some high-risk <strong>surgical</strong> patients (eg, patients with total hip replacement (see  <a class="medical medical_review" href="/z/d/html/1339.html" rel="external">"Prevention of venous thromboembolic disease in adult nonorthopedic surgical patients", section on 'Duration'</a>)), similar benefits have not been consistently observed in patients admitted for acute medical illness [<a href="#rid93">93,94</a>]. Other meta-analyses showed a benefit of extended duration prophylaxis [<a href="#rid95">95,96</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Best illustrating this is a meta-analysis that included the three major randomized trials (EXCLAIM [<a href="#rid30">30,97</a>], ADOPT [<a href="#rid98">98</a>], MAGELLAN [<a href="#rid99">99</a>]), which reported that compared with traditional duration thromboprophylaxis, extended duration thromboprophylaxis (usually with <a class="drug drug_general" data-topicid="9407" href="/z/d/drug information/9407.html" rel="external">enoxaparin</a> or <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">rivaroxaban</a>) was not associated with a reduction in individual rates of symptomatic or asymptomatic DVT, PE, or VTE-related death [<a href="#rid93">93</a>]. Bleeding events were two to three times as likely to occur with extended duration thromboprophylaxis (number needed to harm 194). A subsequent meta-analysis of five trials showed similar results [<a href="#rid100">100</a>]. Other meta-analyses have suggested a benefit of extended duration prophylaxis in reducing symptomatic VTE, but the absolute risk reduction was low (number needed to treat [NNT] to prevent 1 DVT = 313, NNT to prevent 1 nonfatal PE = 625) [<a href="#rid95">95</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Similarly, in another randomized trial of acutely ill hospitalized medical patients (≥40 years) who had an elevated D-dimer, extended prophylaxis for 35 to 42 days with oral betrixaban (80 mg daily) was compared with <a class="drug drug_general" data-topicid="9407" href="/z/d/drug information/9407.html" rel="external">enoxaparin</a> (40 mg daily) administered for 6 to 14 days; three groups were analyzed, patients with an elevated D-dimer, patients with an elevated D-dimer <strong>or</strong> age &gt;75 years, and all patients [<a href="#rid94">94,101</a>]. Betrixaban was associated with a reduction in the rate of VTE (symptomatic and asymptomatic) in the group as a whole (5.3 versus 7 percent) and in patients with an elevated D-Dimer or patients &gt;75 years (5.6 versus 7.1 percent) but was not significant in patients with an elevated D-Dimer alone (6.9 versus 8.5 percent). There was no excess bleeding with extended prophylaxis. However, the analysis plan specified that if the between-group difference in any of the analyses was not significant, the other analyses would be considered exploratory, thereby prohibiting conclusive interpretation. Additional analyses and research are needed to identify specific patient subgroups that may benefit from extended prophylaxis with this agent. Betrixaban is no longer available.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another trial (MARINER), 12,019 patients considered at high risk of VTE were randomly assigned to receive <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">rivaroxaban</a> (10 mg orally daily) or placebo for 45 days following hospital discharge [<a href="#rid102">102</a>]. A 7.5 mg dose was used in a subgroup of patients with impaired renal function (creatinine clearance &lt;50 mL per minute and ≥30 mL per minute). Rates of the composite outcome of symptomatic VTE or VTE-related death were similar among the groups (0.83 for rivaroxaban versus 1.1 percent for placebo; hazard ratio [HR] 0.76, 95% CI 0.52-1.09). However, similar to the effects of rivaroxaban reported in MAGELLAN [<a href="#rid99">99</a>], rivaroxaban in this study lowered the rates of symptomatic nonfatal VTE (0.18 versus 0.42 percent; HR 0.44, 95% CI 0.22-0.89). Although rates of major bleeding were higher in the rivaroxaban group compared with placebo, the overall incidence of major bleeding was low in both groups and without a statistically significant difference (0.28 versus 0.15 percent). The lower rate of VTE events in the placebo group (1.1 percent instead of the expected 2.5 percent) in this study may have resulted in an underestimation of the prophylactic effect of rivaroxaban.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a post-hoc analysis of MARINER and MAGELLAN, <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">rivaroxaban</a> at 10mg per day had a similar efficacy and safety profile in a small subgroup of patients with renal dysfunction compared with the majority of study participants who did not have renal dysfunction [<a href="#rid103">103</a>]. Further trials are needed before rivaroxaban could be considered in this setting.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a subsequent meta-analysis of three randomized trials, extended thromboprophylaxis with betrixaban or <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">rivaroxaban</a> reduced VTE (risk difference [RD] -1.51 percent, 95% CI -2.32 to -0.69 percent) without excess major bleeding (RD 0.12 percent, 95% CI -0.05 to -0.29 percent) [<a href="#rid104">104</a>]. Patients with an elevated D-dimer (ie, greater than twice the upper limit of normal) experienced a greater reduction in VTE than those without an elevated D-Dimer (RD -2.39 versus -0.26 percent). A similar trend was seen in patients aged ≥75 years compared with those younger than 75 years (RD for VTE -2.29 versus -0.63 percent). Betrixaban is no longer available for clinical use.</p><p></p><p class="headingAnchor" id="H2280520893"><span class="h1">METHODS OF THROMBOPROPHYLAXIS</span></p><p class="headingAnchor" id="H79882310"><span class="h2">Pharmacologic thromboprophylaxis</span><span class="headingEndMark"> — </span>In randomized trials, pharmacologic prophylaxis with low molecular weight (LMW) heparin, <a class="drug drug_general" data-topicid="8518" href="/z/d/drug information/8518.html" rel="external">unfractionated heparin</a> (UFH), or <a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">fondaparinux</a> have all been shown to be superior to placebo or mechanical devices in preventing VTE [<a href="#rid38">38,75,76,105-113</a>]. Among these, we prefer LMW heparin because meta-analyses suggest it is superior to UFH (twice daily or three times daily dosing regimens), particularly in high-risk populations (see <a class="local">'High-risk populations'</a> above). Most data from randomized studies suggest that there is no appreciable effect of heparin prophylaxis on mortality and limited effect on bleeding. The quality of data is limited by the heterogeneity of included study populations (low risk and high risk) and the failure to distinguish symptomatic from asymptomatic VTE. <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">Aspirin</a> and <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> should not be used as primary agents for VTE prevention.</p><p class="headingAnchor" id="H17"><span class="h3">Low molecular weight heparin</span></p><p class="headingAnchor" id="H2280521115"><span class="h4">Efficacy</span><span class="headingEndMark"> — </span>Trials comparing LMW heparin with UFH and/or placebo in specific populations are discussed below:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>General medical</strong> <strong>populations</strong> – Examples of randomized studies and meta-analyses that illustrate the value of pharmacologic prophylaxis in general medical populations include the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>One meta-analysis of 36 randomized trials of a <strong>mixed</strong> population of hospitalized medical patients that included those at low and high risk for VTE, compared heparin with placebo for the prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE) [<a href="#rid75">75</a>]. Both UFH and LMW heparin reduced the risk of DVT (risk ratio [RR] 0.33, 95% CI 0.26-0.42; RR 0.56, 95% CI 0.45-0.7, respectively) and PE (RR 0.64, 95% CI 0.50-0.82; RR 0.37, 95% CI 0.21-0.64, respectively) without any effect on mortality. When compared with UFH, use of LMW heparin was associated with a lower risk of DVT (RR 0.68, 95% CI 0.52-0.88) but no difference was reported between the two agents in the risk of bleeding or thrombocytopenia.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Another meta-analysis of 16 randomized studies reported similar results in a population of over 34,000 medical patients that <strong>excluded</strong> <strong>those at high risk</strong> for VTE (myocardial infarction, stroke, intensive care unit patients) [<a href="#rid112">112</a>]. In that population, compared with placebo, both UFH and LMW heparin reduced the risk of DVT (odds ratio [OR] 0.38, 95% CI 0.29-0.51) as well as symptomatic and fatal PE (OR 0.65, 95% CI 0.42-1) with no effect on mortality and thrombocytopenia. However, an increase in major hemorrhage was reported with use of heparin (OR 1.81, 95% CI 1.1-2.98). Compared with UFH, LMW heparin was associated with a reduced risk of DVT (OR 0.77, 95% CI 0.62-0.96) and lower rates of major bleeding (OR 0.43, 95% CI 0.22-0.83).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Another meta-analysis of 44 randomized trials (over 90,000 mostly medical patients) reported that all pharmacologic anticoagulants reduced symptomatic VTE compared with placebo and that none offered a mortality benefit [<a href="#rid114">114</a>]. Among the agents, those that offered superior efficacy for preventing VTE included intermediate dose LMW heparin (OR 0.66, 95% CI 0.46-0.93), direct oral anticoagulants (DOACs; 0.68, 95% CI 0.33-1.34), and intermediate dose <a class="drug drug_general" data-topicid="8518" href="/z/d/drug information/8518.html" rel="external">unfractionated heparin</a> (0.71, 95% CI 0.43-1.19) (very low to low quality evidence). However, bleeding rates were higher with intermediate dose unfractionated heparin (2.63, 95% CI 1.00 to 6.21) and DOACs (2.31, 95% CI 0.82-6.47) (low to moderate quality evidence).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>High-risk populations</strong> – Studies have also investigated the use of prophylaxis in select populations considered to be at <strong>high risk</strong> for VTE:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Stroke</strong> – In patients with leg paralysis from ischemic stroke, data derived from randomized studies reported that, compared with UFH, LMW heparin was associated with a greater risk reduction for VTE with no significant increase in clinically relevant bleeding [<a href="#rid80">80,115-117</a>]. (See  <a class="medical medical_review" href="/z/d/html/121857.html" rel="external">"Prevention and treatment of venous thromboembolism in patients with acute stroke", section on 'Approach to VTE prevention'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Critically ill</strong> – Randomized trials and meta-analyses have examined the importance of prophylaxis in the critically ill [<a href="#rid118">118-122</a>]. As examples:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>One network meta-analysis of 13 randomized trials that enrolled a total of 9619 critically ill patients reported that LMW heparin reduced the incidence of all DVT (OR 0.59, 95% CI 0.33-0.90; high certainty) when compared with control treatment (a composite of no prophylaxis, placebo, or compression stockings only) [<a href="#rid122">122</a>]. LMW heparin appeared to be more effective than UFH (OR 0.72, 95% CI 0.46-0.98; moderate certainty), and mechanical methods of thromboprophylaxis (eg, intermittent compressive devices) were least effective (OR 0.85, 95% CI 0.50-1.50; low certainty). The effect of combination therapy was unclear.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Another randomized trial (PROTECT) of 3764 critically ill patients directly compared UFH with the LMW heparin, <a class="drug drug_general" data-topicid="9319" href="/z/d/drug information/9319.html" rel="external">dalteparin</a> [<a href="#rid119">119</a>]. Dalteparin was associated with a rate reduction in PE (1 versus 2 percent; hazard ratio 0.5) but had no effect on DVT, bleeding, mortality, or cost [<a href="#rid119">119,121</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Older patients</strong> – A meta-analysis of 5657 patients ≥75 years of age showed that, compared with placebo, prophylaxis reduced the incidence of VTE (4 versus 11 percent) without affecting bleeding events, or all-cause mortality [<a href="#rid111">111</a>]. However, among all the VTE events seen in the placebo group (symptomatic and asymptomatic DVT, PE and fatal PE), two-thirds were asymptomatic or ultrasound-detected DVT. Although major bleeding events were rare (1.1 versus 0.7 percent; OR 1.77, 95% CI 0.52-6.08), the wide confidence limits suggest that some patients are more at risk for bleeding than others. Further randomized studies are required to assess the safety and efficacy of VTE prophylaxis in the older population. (See <a class="local">'Assess risk'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients hospitalized with COVID-19</strong> – Such patients represent a special population at markedly increased risk for VTE, especially if critically ill in an intensive care unit setting. The use of anticoagulants as prophylaxis against COVID-19-associated VTE is covered elsewhere. (See  <a class="medical medical_review" href="/z/d/html/127926.html" rel="external">"COVID-19: Hypercoagulability"</a>.)</p><p></p><p class="headingAnchor" id="H2280521121"><span class="h4">Dosing</span><span class="headingEndMark"> — </span>A number of LMW heparin preparations are available (<a class="drug drug_general" data-topicid="9407" href="/z/d/drug information/9407.html" rel="external">enoxaparin</a>, <a class="drug drug_general" data-topicid="9319" href="/z/d/drug information/9319.html" rel="external">dalteparin</a>, <a class="drug drug_general" data-topicid="10009" href="/z/d/drug information/10009.html" rel="external">tinzaparin</a>, <a class="drug drug_general" data-topicid="10060" href="/z/d/drug information/10060.html" rel="external">nadroparin</a>), none of which have proven superiority over the other when administered as agents to prevent VTE. Suggested prophylactic doses for <strong>medical</strong> patients with a creatinine clearance &gt;30 mL/minute and assuming no extremes in body weight are the following:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9407" href="/z/d/drug information/9407.html" rel="external">Enoxaparin</a> 40 mg subcutaneously once daily</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9319" href="/z/d/drug information/9319.html" rel="external">Dalteparin</a> 5000 units subcutaneously once daily</p><p></p><p>Less commonly used are:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10009" href="/z/d/drug information/10009.html" rel="external">Tinzaparin</a> 4500 anti-Xa subcutaneously once daily</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10060" href="/z/d/drug information/10060.html" rel="external">Nadroparin</a> 3800 anti-Xa units/day in patients ≤70 kg and 5700 units per day in patients &gt;70 kg once daily</p><p></p><p>The platelet count may be monitored regularly (eg, day 5 and 9) in all patients receiving LMW heparin to detect the development of heparin-induced thrombocytopenia (HIT). All LMW heparin agents are contraindicated in patients with HIT. Management of heparin anticoagulants in patients with HIT is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1369.html" rel="external">"Management of heparin-induced thrombocytopenia"</a>.)</p><p>The ideal dose for patients with obesity, typically defined as those with a body weight greater than 100 kg, is unknown. Dosing should be individualized on a case-by-case basis. We generally prefer to empirically treat these patients with UFH (see <a class="local">'Low-dose unfractionated heparin'</a> below). An alternative approach used with LMW heparin prophylaxis is to increase the dose by 50 percent (eg, <a class="drug drug_general" data-topicid="9407" href="/z/d/drug information/9407.html" rel="external">enoxaparin</a> 60 mg once daily or <a class="drug drug_general" data-topicid="9319" href="/z/d/drug information/9319.html" rel="external">dalteparin</a> 7500 units once daily).</p><p>Based upon data extrapolated from patients receiving therapeutic doses of LMW heparin, some experts prefer the avoidance of these agents in patients with severe renal insufficiency (eg, creatinine clearance &lt;30 mL/min) should it be present upon admission or develop during hospitalization. However, we and other experts continue to use selected LMW heparins in patients with renal insufficiency (eg, <a class="drug drug_general" data-topicid="10009" href="/z/d/drug information/10009.html" rel="external">tinzaparin</a> and <a class="drug drug_general" data-topicid="9319" href="/z/d/drug information/9319.html" rel="external">dalteparin</a>) but a dose reduction of <a class="drug drug_general" data-topicid="9407" href="/z/d/drug information/9407.html" rel="external">enoxaparin</a> is needed for those with severe renal insufficiency  (<a class="graphic graphic_table graphicRef90258" href="/z/d/graphic/90258.html" rel="external">table 1</a>). For those who develop severe renal insufficiency during hospitalization, it is prudent that selected LMW heparins be discontinued and replaced with UFH. (See  <a class="medical medical_review" href="/z/d/html/1348.html" rel="external">"Heparin and LMW heparin: Dosing and adverse effects"</a>.)</p><p class="headingAnchor" id="H18"><span class="h3">Low-dose unfractionated heparin</span></p><p class="headingAnchor" id="H2280521127"><span class="h4">Efficacy</span><span class="headingEndMark"> — </span>Thromboprophylactic doses of UFH are effective at preventing VTE when compared with placebo or mechanical devices. However, when compared with UFH, LMW heparin appears to be marginally superior for the prevention of VTE, the details of which are discussed separately. (See <a class="local">'Low molecular weight heparin'</a> above.)</p><p class="headingAnchor" id="H2280521133"><span class="h4">Dosing</span><span class="headingEndMark"> — </span>Typical prophylactic dosing for UFH is 5000 units subcutaneously twice or three times daily. The frequency of UFH dosing is controversial. While one meta-analysis of 12 randomized studies, reported a nonsignificant reduction in the overall rate of VTE with three times daily compared with twice daily UFH heparin dosing (3.5 versus 5.4 events/1000 patient-days), the risk for major bleeding was significantly greater (0.96/1000 patient-days versus 0.35/1000 patient-days) [<a href="#rid123">123</a>]. In a second meta-analysis, when compared with placebo, UFH injected three times daily was more effective in preventing DVT than a twice daily dosing regimen (RR 0.27; versus RR 0.52; 95% CI 0.28-0.96) [<a href="#rid75">75</a>]. However, a third meta-analysis found no difference between twice and three times daily UFH dosing in the rates of VTE, VTE-related death, or major bleeding [<a href="#rid124">124</a>]. Our preference is for twice daily UFH dosing since the evidence to support three times daily is inconclusive. Factors including cost, institutional policy, body weight, and risk of bleeding may also be used to help the clinician make the decision to choose the frequency of dosing.</p><p>The ideal dose for patients with obesity is unknown, such that dosing should be individualized on a case-by-case basis. We generally prefer to empirically treat with UFH 5000 to 7500 units three times daily; alterations in the dosing and frequency should be tailored to individual patients.</p><p>Compared with LMW heparin, the dose of UFH does not need to be adjusted for patients with renal failure. In addition, in some countries, low-dose UFH has the advantage of being inexpensive. However, similar to LMW heparin, UFH is contraindicated in patients with heparin-induced thrombocytopenia (HIT) and the platelet count should be monitored regularly (eg, days 5 and 9) in all patients receiving low-dose UFH to detect the development of HIT [<a href="#rid125">125,126</a>]. (See  <a class="medical medical_review" href="/z/d/html/1348.html" rel="external">"Heparin and LMW heparin: Dosing and adverse effects", section on 'Platelet count monitoring'</a>.)</p><p class="headingAnchor" id="H21"><span class="h3">Fondaparinux</span></p><p class="headingAnchor" id="H2280521149"><span class="h4">Efficacy</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">Fondaparinux</a> is superior to placebo and probably as effective as LMW heparin for patients who are not critically ill, although compared with LMW heparin, very little data are available to support its routine use.</p><p><a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">Fondaparinux</a> (2.5 mg subcutaneously once daily) was compared with placebo in 849 medical patients ≥60 years of age, hospitalized due to acute cardiac, respiratory, infectious, or inflammatory disease, who were expected to remain in bed for at least four days, and considered to be at moderate risk for VTE (ARTEMIS) [<a href="#rid72">72</a>]. There was a significant reduction in the rate of symptomatic and asymptomatic VTE (11 versus 6 percent). Major bleeding occurred in one patient (0.2 percent) in each group. This study is discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/1319.html" rel="external">"Fondaparinux: Dosing and adverse effects"</a>.)</p><p class="headingAnchor" id="H2280521155"><span class="h4">Dosing</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">Fondaparinux</a> is typically administered as 2.5 mg subcutaneously once daily. Fondaparinux should be avoided in those with a creatinine clearance &lt;30 mL/min. If necessary, a dose reduction to 1.5 mg subcutaneously daily can be used in those with a creatinine clearance in the range of 30 to 50 mL/min [<a href="#rid127">127</a>]. The safety and efficacy of reduced dosing was tested in a multicenter prospective cohort study in 206 acutely ill older (mean age 82 years) medical patients (mean creatinine clearance 33 mL/minute [range 20 to 50 mL/min]) at high risk for both bleeding and thrombosis [<a href="#rid128">128</a>]. Symptomatic VTE developed in three patients (1.5 percent) and major bleeding occurred in only one patient (0.5 percent).</p><p class="headingAnchor" id="H22"><span class="h3">Aspirin</span><span class="headingEndMark"> — </span>We agree with others that <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> <strong>not</strong> be used, either alone or in combination, as prophylaxis against VTE in any medical patient group [<a href="#rid66">66</a>]. Although aspirin, is highly effective in reducing major <strong>arterial</strong> thrombotic events, there is little evidence that aspirin and/or other antiplatelet agents (eg, <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a>) can prevent <strong>venous</strong> thromboembolic events in hospitalized medical patients. Although a 1994 meta-analysis suggested that aspirin reduced the incidence of VTE by approximately 20 percent compared with placebo or no treatment [<a href="#rid129">129,130</a>], studies since then have shown either no significant benefit or inferiority when compared with other modalities such as LMW heparin [<a href="#rid130">130</a>].</p><p>In the community setting, <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> does not appear to reduce the overall risk of VTE prior to admission, the details of which are discussed separately. (See <a class="local">'Effect of statin or aspirin on risk'</a> above.)</p><p>In contrast, <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> has been shown to decrease the recurrence rate in patients with a first episode of VTE, the details of which are also discussed separately. (See  <a class="medical medical_review" href="/z/d/html/94740.html" rel="external">"Selecting adult patients with lower extremity deep venous thrombosis and pulmonary embolism for indefinite anticoagulation"</a>.)</p><p class="headingAnchor" id="H23"><span class="h3">Warfarin</span><span class="headingEndMark"> — </span>Initiating <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> in patients who are not already anticoagulated is not appropriate for immediate and short-term (ie, one month or less) prevention of VTE; the anticoagulant effect is delayed and does not occur until 36 to 72 hours after drug administration. In addition, hospitalized medical patients often have comorbidities (eg, impaired liver function) and/or are on medications that interfere with consistent prediction of the anticoagulant effect. (See  <a class="medical medical_review" href="/z/d/html/1334.html" rel="external">"Warfarin and other VKAs: Dosing and adverse effects"</a> and  <a class="medical medical_review" href="/z/d/html/1337.html" rel="external">"Biology of warfarin and modulators of INR control", section on 'Mechanism of action'</a>.)</p><p class="headingAnchor" id="H3359988118"><span class="h3">Direct oral anticoagulants</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">Rivaroxaban</a> is approved for use in hospitalized medically ill patients [<a href="#rid131">131,132</a>]. In a study of over 7000 hospitalized medically ill patients, compared with <a class="drug drug_general" data-topicid="9407" href="/z/d/drug information/9407.html" rel="external">enoxaparin</a>, the composite outcome of asymptomatic and symptomatic VTE plus VTE-related death was reduced in patients taking betrixaban (which is no longer available) compared with subcutaneous enoxaparin (4.4 versus 6 percent) without any increase in the bleeding rate [<a href="#rid101">101</a>]. Rivaroxaban has been studied in the extended duration setting [<a href="#rid99">99,133</a>]. These studies are discussed above. (See <a class="local">'Duration of prophylaxis'</a> above.)</p><p>Dosing in patients with obesity is unclear. The International Society on Thrombosis and Hemostasis suggest that for patients with a body mass index (BMI) &gt;40 kg/m<sup>2</sup> or weight &gt;120 kg, that standard dosing for <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">rivaroxaban</a> and <a class="drug drug_general" data-topicid="85642" href="/z/d/drug information/85642.html" rel="external">apixaban</a> rather than other DOACs can be used in this population [<a href="#rid134">134</a>].</p><p class="headingAnchor" id="H24"><span class="h2">Mechanical methods of thromboprophylaxis</span><span class="headingEndMark"> — </span>We agree with others that mechanical methods for the prevention of VTE are primarily indicated in patients at high risk of bleeding or in whom anticoagulation is contraindicated (eg, gastrointestinal or intracranial hemorrhage) [<a href="#rid66">66</a>]. When used in these circumstances, transition to a pharmacologic agent should be considered as soon as the bleeding risk becomes acceptably low or has been reversed [<a href="#rid66">66</a>]. Data that supports this approach are derived mostly from surgical patients and limited data performed in acutely ill hospitalized medical patients.</p><p>Options include intermittent pneumatic compression, graduated compression stockings, and venous foot pumps. Neuromuscular electrical stimulation remains investigational [<a href="#rid135">135</a>].</p><p class="headingAnchor" id="H25"><span class="h3">Intermittent pneumatic compression</span><span class="headingEndMark"> — </span>Intermittent pneumatic compression (IPC)  (<a class="graphic graphic_picture graphicRef102817" href="/z/d/graphic/102817.html" rel="external">picture 1</a>) prevents DVT by enhancing blood flow in the deep veins of the legs, thereby preventing venous stasis [<a href="#rid136">136</a>]. IPC also reduces plasminogen activator inhibitor-1 (PAI-1), thereby increasing endogenous fibrinolytic activity [<a href="#rid137">137</a>]. (See  <a class="medical medical_review" href="/z/d/html/1326.html" rel="external">"Thrombotic and hemorrhagic disorders due to abnormal fibrinolysis", section on 'PAI-1'</a>.)</p><p>IPC devices are an alternative for VTE prevention in medical patients with a high risk of bleeding or in whom anticoagulant drugs are contraindicated (eg, GI bleeding, intracranial hemorrhage) [<a href="#rid66">66</a>]. Although there are no data available on skin complications of IPC use, skin breakdown is a known complication, especially in the frail older adult population. IPC devices are also contraindicated in patients with evidence of leg ischemia due to peripheral vascular disease. Attention must be paid to optimal compliance, as well as proper fit of the IPC device.</p><p>Data on the efficacy and safety of IPCs are limited. However, one large randomized trial in patients with stroke suggested that IPCs reduce the incidence of VTE [<a href="#rid138">138</a>]. A multicenter, randomized trial of 2876 immobile patients with acute stroke (CLOTS 3) reported that, compared with no device, IPC use was associated with a lower rate of VTE at 30 days (12 versus 8.5 percent) without altering mortality (13 versus 11 percent). However, the use of LMW heparin was similar in both groups (32 versus 30 percent). Further results of this trial and clot prevention in patients with stroke are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/121857.html" rel="external">"Prevention and treatment of venous thromboembolism in patients with acute stroke", section on 'Intermittent pneumatic compression'</a>.)</p><p>Contraindications to anticoagulant prophylaxis are discussed above. (See <a class="local">'Bleeding risk assessment'</a> above.)</p><p class="headingAnchor" id="H26"><span class="h3">Graduated compression stockings and venous foot pump</span><span class="headingEndMark"> — </span>There is even less convincing evidence regarding the efficacy of graduated compression stockings (GCS) and venous foot pumps (VFP) in medical patients  (<a class="graphic graphic_picture graphicRef102819" href="/z/d/graphic/102819.html" rel="external">picture 2</a>).</p><p>In a meta-analysis, GCS was found to be ineffective in the prevention of VTE in patients with ischemic stroke [<a href="#rid139">139</a>]. One randomized trial of stroke patients showed that thigh-length GCS was associated with no benefit with respect to reduction of VTE, along with a four-fold increase in skin ulcers and necrosis [<a href="#rid140">140</a>]. The use of GCS to prevent VTE following stroke is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/121857.html" rel="external">"Prevention and treatment of venous thromboembolism in patients with acute stroke", section on 'Ineffective or unproven treatments'</a>.)</p><p>Similarly, randomized studies showing efficacy of VFP devices in medical patients are lacking and most data to support their use are derived from the surgical population [<a href="#rid141">141</a>]. In theory, they prevent thrombosis by stimulating lower limb venous flow at the level of the foot [<a href="#rid142">142</a>].</p><p class="headingAnchor" id="H2349553350"><span class="h2">Combined methods</span><span class="headingEndMark"> — </span>Despite the widespread practice of combining mechanical and pharmacologic methods of thromboprophylaxis, few studies have systematically examined the efficacy of this approach on the rates of VTE or VTE-related death in acutely ill hospitalized medical patients. One large randomized trial assessing the use of GCS in medical patients, with or without low-dose LMW heparin, found no added mortality benefit with the use of LMW heparin. However, this trial may have been underpowered to detect a significant difference in mortality [<a href="#rid34">34</a>]. A second randomized trial (PREVENT) of 2003 critically ill patients, 80 percent of whom were medical intensive care unit patients, reported that the addition of intermittent pneumatic compression (IPC) for at least 18 hours a day to unfractionated or LMW heparin did not reduce the rate of ultrasound-detected deep venous thrombosis (3.9 versus 4.2 percent) or symptomatic pulmonary embolism (0.8 versus 1.0 percent) or death from any cause (26 percent each) [<a href="#rid143">143</a>]. However the incidence of VTE was lower than expected in the control group, thereby reducing the power of the trial to detect a difference between the groups. The value of combined prophylaxis in surgical patients is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1339.html" rel="external">"Prevention of venous thromboembolic disease in adult nonorthopedic surgical patients", section on 'With low bleeding risk: Combined prophylaxis'</a>.)</p><p class="headingAnchor" id="H4051618252"><span class="h1">ANTICOAGULANTS IN DEVELOPMENT</span><span class="headingEndMark"> — </span>Anticoagulants in development for thrombosis prophylaxis are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/138700.html" rel="external">"Investigational anticoagulants"</a>.)</p><p class="headingAnchor" id="H1842894749"><span class="h1">QUALITY IMPROVEMENT INITIATIVES</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>National programs</strong> – The prevention of venous thromboembolism (VTE) is a major patient safety issue in hospitals according to the Agency for Health Care Research and Quality [<a href="#rid144">144</a>]. As an example, the Center for Medicare and Medicaid Services (CMS) considers appropriate VTE prophylaxis to be a pay-for-performance quality measure for specific surgical procedures [<a href="#rid145">145</a>].</p><p></p><p class="bulletIndent1">Thus, in the United States there have been a number of initiatives aimed at calling attention to the prevalence of VTE and advocating for increased use of VTE prophylaxis in hospitalized patients. These initiatives have come from The National Quality Forum [<a href="#rid146">146</a>], The Surgical Care Improvement Project [<a href="#rid115">115</a>], the Centres for Medicine and Medicinal Services, the Joint Commission on Accreditation of Health Care Organizations [<a href="#rid147">147</a>], and the Office of the Surgeon General of the United States [<a href="#rid148">148</a>]. Similar initiatives have been developed in Canada [<a href="#rid149">149</a>], the United Kingdom [<a href="#rid70">70,150</a>], and Europe.</p><p></p><p class="bulletIndent1">However, despite these efforts, numerous audits and reviews have demonstrated that appropriate thromboprophylaxis is not being offered to large numbers of patients, particularly those hospitalized with medical conditions [<a href="#rid105">105,151-160</a>]. Reasons for this may include contraindications to anticoagulants or altered risk as the patient progresses throughout their admission as well as clinician reluctance to change practice.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hospital decision support programs</strong> – Various strategies designed to improve the appropriate use of thromboprophylaxis have shown inconsistent or unproven effects on reducing VTE incidence [<a href="#rid161">161-166</a>]. Such strategies include clinician alerts, computerized order sets with electronic alerts or pre-printed orders, risk assessment models, and quality improvement in the form of audit and feedback. Despite the existence of such programs, formal educational programs for involved health care professionals may still be needed in order to significantly improve the appropriate use of thromboprophylaxis [<a href="#rid167">167,168</a>]. Further efforts are required at improving the translation of data from clinical trials into clinical practice [<a href="#rid86">86,169-178</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Predictive models</strong> – Predictive models that identify those at greatest risk and in need of thromboprophylaxis have been reported. As an example, one database analysis identified factors independently associated with VTE as previous VTE, known thrombophilia, cancer, age &gt;60 years, lower-limb paralysis, immobilization for seven days or longer, and admission to an ICU or coronary care unit [<a href="#rid39">39</a>]. Points were assigned to each factor identified to give a total risk score for each patient. During hospitalization, a score ≥2 was associated with higher overall and VTE-related mortality. Predictive models such as these need validation before they can be routinely used at the time of admission or during hospitalization to identify those at greatest risk in whom thromboprophylaxis should be administered.</p><p></p><p class="headingAnchor" id="H2077320366"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/113663.html" rel="external">"Society guideline links: Superficial vein thrombosis, deep vein thrombosis, and pulmonary embolism"</a>.)</p><p class="headingAnchor" id="H1842896192"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/693.html" rel="external">"Patient education: Deep vein thrombosis (DVT) (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/689.html" rel="external">"Patient education: Warfarin (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H31"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> <strong>and thrombosis risk</strong> – While many studies report venous thromboembolism (VTE) rates in the absence of prophylaxis that range from 10 to 80 percent, these rates are likely overestimated.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>General medical patients</strong> – While thromboprophylaxis reduces the risk of VTE in hospitalized medical patients, mortality benefits are unclear in this population. Importantly, clinicians should be aware that VTE prophylaxis does not eliminate the risk of VTE or VTE-related death. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>High-risk patient groups</strong> – Patients at highest risk of VTE include patients who are critically ill, patients with cancer or stroke, and patients with multiple risk factors for VTE including pregnancy, heart failure, myocardial infarction, old age (&gt;75 years), previous VTE, prolonged immobility, renal failure, obesity, and inherited or acquired hypercoagulable states. (See <a class="local">'Epidemiology'</a> above and  <a class="medical medical_review" href="/z/d/html/1361.html" rel="external">"Overview of the causes of venous thrombosis"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Risk assessment</strong> – For patients admitted to the hospital with an acute medical illness, a full history and examination should be performed to assess both the risk of VTE and bleeding. However, validated models for evaluating this risk in hospitalized medical patients are lacking. (See <a class="local">'Assess risk'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Low-risk patients</strong> – For hospitalized medical patients without obvious risk factors for VTE, we recommend that pharmacologic thromboprophylaxis <strong>not</strong> be employed. Options for this low-risk group include early ambulation with or without mechanical methods of thromboprophylaxis. (See <a class="local">'Selection of method of prophylaxis'</a> above and <a class="local">'Mechanical methods of thromboprophylaxis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Moderate- or high-risk patients</strong> – For most patients hospitalized with an acute medical illness who have at least one risk factor for VTE (moderate or high risk) and do not have an increased risk of bleeding, we recommend the use of pharmacologic thromboprophylaxis rather than mechanical methods or no prophylaxis (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Agent of choice</strong> – Among the available agents, we prefer low molecular weight heparin rather than other anticoagulants  (<a class="graphic graphic_table graphicRef90258" href="/z/d/graphic/90258.html" rel="external">table 1</a>) (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>), particularly in high-risk populations (eg, critically ill, cancer, stroke).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Alternatives</strong> – For those with renal failure (creatinine clearance &lt;30 mL/min) or for those in whom cost is an issue, <a class="drug drug_general" data-topicid="8518" href="/z/d/drug information/8518.html" rel="external">unfractionated heparin</a> is a reasonable alternative. For patients with heparin-induced thrombocytopenia, <a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">fondaparinux</a> may be used as an alternative to heparin. (See <a class="local">'Selection of method of prophylaxis'</a> above and <a class="local">'Pharmacologic thromboprophylaxis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Combined prophylaxis</strong> – While some experts administer more aggressive prophylaxis in the form of increased intensity of a pharmacologic agent or the addition of a mechanical device, data do not support this approach in medical patients. (See <a class="local">'Combined methods'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients at risk of bleeding</strong> – For most patients hospitalized with an acute medical illness who have risk factors for VTE and who are at high risk of bleeding or in whom anticoagulation is contraindicated (eg, gastrointestinal or intracranial hemorrhage), mechanical methods of VTE prevention (eg, intermittent pneumatic compression, graduated compression stockings, venous foot pump  (<a class="graphic graphic_picture graphicRef102817" href="/z/d/graphic/102817.html" rel="external">picture 1</a>)) are suggested over no prophylaxis (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Transition to a pharmacologic agent should occur as soon as the bleeding risk becomes acceptably low or has been reversed. (See <a class="local">'Mechanical methods of thromboprophylaxis'</a> above and <a class="local">'At risk of bleeding'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Special populations</strong> – Special populations of medical patients require an individualized approach to thromboprophylaxis during an acute hospitalization. These include patients with heparin-induced thrombocytopenia, patients undergoing neuraxial anaesthesia or analgesia, patients with stroke or cancer, patients who are traveling for extended periods, and patients who are pregnant. (See  <a class="medical medical_review" href="/z/d/html/14930.html" rel="external">"Neuraxial anesthesia/analgesia techniques in the patient receiving anticoagulant or antiplatelet medication"</a> and  <a class="medical medical_review" href="/z/d/html/1352.html" rel="external">"Risk and prevention of venous thromboembolism in adults with cancer"</a> and  <a class="medical medical_review" href="/z/d/html/1347.html" rel="external">"Venous thromboembolism in pregnancy: Prevention"</a> and  <a class="medical medical_review" href="/z/d/html/121857.html" rel="external">"Prevention and treatment of venous thromboembolism in patients with acute stroke"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Duration</strong> – VTE prophylaxis should typically continue until the patient is ambulatory or discharged from the hospital. We suggest <strong>not</strong> routinely extending the duration of thromboprophylaxis beyond the period of the acute hospital stay (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). However, select populations may benefit from extended duration prophylaxis including nonambulatory patients admitted to acute rehabilitation for weaning from mechanical ventilation. (See <a class="local">'Duration of prophylaxis'</a> above.)</p><p></p><p class="headingAnchor" id="H209395294"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Menaka Pai, MD, FRCPC, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Anderson FA Jr, Zayaruzny M, Heit JA, et al. Estimated annual numbers of US acute-care hospital patients at risk for venous thromboembolism. Am J Hematol 2007; 82:777.</a></li><li><a class="nounderline abstract_t">Lindblad B, Eriksson A, Bergqvist D. Autopsy-verified pulmonary embolism in a surgical department: analysis of the period from 1951 to 1988. Br J Surg 1991; 78:849.</a></li><li><a class="nounderline abstract_t">Stein PD, Henry JW. Prevalence of acute pulmonary embolism among patients in a general hospital and at autopsy. Chest 1995; 108:978.</a></li><li><a class="nounderline abstract_t">White RH, Zhou H, Romano PS. Incidence of symptomatic venous thromboembolism after different elective or urgent surgical procedures. Thromb Haemost 2003; 90:446.</a></li><li><a class="nounderline abstract_t">Sandler DA, Martin JF. Autopsy proven pulmonary embolism in hospital patients: are we detecting enough deep vein thrombosis? J R Soc Med 1989; 82:203.</a></li><li><a class="nounderline abstract_t">Martino MA, Borges E, Williamson E, et al. Pulmonary embolism after major abdominal surgery in gynecologic oncology. Obstet Gynecol 2006; 107:666.</a></li><li><a class="nounderline abstract_t">Dismuke SE, Wagner EH. Pulmonary embolism as a cause of death. The changing mortality in hospitalized patients. JAMA 1986; 255:2039.</a></li><li><a class="nounderline abstract_t">Horlander KT, Mannino DM, Leeper KV. Pulmonary embolism mortality in the United States, 1979-1998: an analysis using multiple-cause mortality data. Arch Intern Med 2003; 163:1711.</a></li><li><a class="nounderline abstract_t">Dobromirski M, Cohen AT. How I manage venous thromboembolism risk in hospitalized medical patients. Blood 2012; 120:1562.</a></li><li><a class="nounderline abstract_t">Heit JA, O'Fallon WM, Petterson TM, et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med 2002; 162:1245.</a></li><li><a class="nounderline abstract_t">Prandoni P, Samama MM. Risk stratification and venous thromboprophylaxis in hospitalized medical and cancer patients. Br J Haematol 2008; 141:587.</a></li><li><a class="nounderline abstract_t">Caprini JA, Arcelus JI, Reyna JJ. Effective risk stratification of surgical and nonsurgical patients for venous thromboembolic disease. Semin Hematol 2001; 38:12.</a></li><li><a class="nounderline abstract_t">Gangireddy C, Rectenwald JR, Upchurch GR, et al. Risk factors and clinical impact of postoperative symptomatic venous thromboembolism. J Vasc Surg 2007; 45:335.</a></li><li><a class="nounderline abstract_t">Haas SK, Hach-Wunderle V, Mader FH, et al. An evaluation of venous thromboembolic risk in acutely ill medical patients immobilized at home: the AT-HOME Study. Clin Appl Thromb Hemost 2007; 13:7.</a></li><li><a class="nounderline abstract_t">Anderson FA Jr, Spencer FA. Risk factors for venous thromboembolism. Circulation 2003; 107:I9.</a></li><li><a class="nounderline abstract_t">Samama MM. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. Arch Intern Med 2000; 160:3415.</a></li><li><a class="nounderline abstract_t">Memtsoudis SG, Della Valle AG, Besculides MC, et al. Risk factors for perioperative mortality after lower extremity arthroplasty: a population-based study of 6,901,324 patient discharges. J Arthroplasty 2010; 25:19.</a></li><li><a class="nounderline abstract_t">Cohen AT, Alikhan R, Arcelus JI, et al. Assessment of venous thromboembolism risk and the benefits of thromboprophylaxis in medical patients. Thromb Haemost 2005; 94:750.</a></li><li><a class="nounderline abstract_t">Chopard P, Spirk D, Bounameaux H. Identifying acutely ill medical patients requiring thromboprophylaxis. J Thromb Haemost 2006; 4:915.</a></li><li><a class="nounderline abstract_t">Zakai NA, Wright J, Cushman M. Risk factors for venous thrombosis in medical inpatients: validation of a thrombosis risk score. J Thromb Haemost 2004; 2:2156.</a></li><li><a class="nounderline abstract_t">Cook D, Crowther M, Meade M, et al. Deep venous thrombosis in medical-surgical critically ill patients: prevalence, incidence, and risk factors. Crit Care Med 2005; 33:1565.</a></li><li><a class="nounderline abstract_t">Samama MM, Dahl OE, Quinlan DJ, et al. Quantification of risk factors for venous thromboembolism: a preliminary study for the development of a risk assessment tool. Haematologica 2003; 88:1410.</a></li><li><a class="nounderline abstract_t">Osborne NH, Wakefield TW, Henke PK. Venous thromboembolism in cancer patients undergoing major surgery. Ann Surg Oncol 2008; 15:3567.</a></li><li><a class="nounderline abstract_t">McColl MD, Walker ID, Greer IA. Risk factors for venous thromboembolism in pregnancy. Curr Opin Pulm Med 1999; 5:227.</a></li><li><a class="nounderline abstract_t">Walker MC, Garner PR, Keely EJ, et al. Changes in activated protein C resistance during normal pregnancy. Am J Obstet Gynecol 1997; 177:162.</a></li><li><a class="nounderline abstract_t">Heit JA, Melton LJ 3rd, Lohse CM, et al. Incidence of venous thromboembolism in hospitalized patients vs community residents. Mayo Clin Proc 2001; 76:1102.</a></li><li><a class="nounderline abstract_t">Collins R, Scrimgeour A, Yusuf S, Peto R. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopedic, and urologic surgery. N Engl J Med 1988; 318:1162.</a></li><li><a class="nounderline abstract_t">Prevention of fatal postoperative pulmonary embolism by low doses of heparin. An international multicentre trial. Lancet 1975; 2:45.</a></li><li><a class="nounderline abstract_t">Samama MM, Cohen AT, Darmon JY, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med 1999; 341:793.</a></li><li><a class="nounderline abstract_t">Hull RD, Schellong SM, Tapson VF, et al. Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial. Ann Intern Med 2010; 153:8.</a></li><li><a class="nounderline abstract_t">Halkin H, Goldberg J, Modan M, Modan B. Reduction of mortality in general medical in-patients by low-dose heparin prophylaxis. Ann Intern Med 1982; 96:561.</a></li><li><a class="nounderline abstract_t">Gärdlund B. Randomised, controlled trial of low-dose heparin for prevention of fatal pulmonary embolism in patients with infectious diseases. The Heparin Prophylaxis Study Group. Lancet 1996; 347:1357.</a></li><li><a class="nounderline abstract_t">Mahé I, Bergmann JF, d'Azémar P, et al. Lack of effect of a low-molecular-weight heparin (nadroparin) on mortality in bedridden medical in-patients: a prospective randomised double-blind study. Eur J Clin Pharmacol 2005; 61:347.</a></li><li><a class="nounderline abstract_t">Kakkar AK, Cimminiello C, Goldhaber SZ, et al. Low-molecular-weight heparin and mortality in acutely ill medical patients. N Engl J Med 2011; 365:2463.</a></li><li><a class="nounderline abstract_t">Lederle FA, Zylla D, MacDonald R, Wilt TJ. Venous thromboembolism prophylaxis in hospitalized medical patients and those with stroke: a background review for an American College of Physicians Clinical Practice Guideline. Ann Intern Med 2011; 155:602.</a></li><li><a class="nounderline abstract_t">Lester W, Freemantle N, Begaj I, et al. Fatal venous thromboembolism associated with hospital admission: a cohort study to assess the impact of a national risk assessment target. Heart 2013; 99:1734.</a></li><li><a class="nounderline abstract_t">Heit JA, Crusan DJ, Ashrani AA, et al. Effect of a near-universal hospitalization-based prophylaxis regimen on annual number of venous thromboembolism events in the US. Blood 2017; 130:109.</a></li><li><a class="nounderline abstract_t">Dentali F, Douketis JD, Gianni M, et al. Meta-analysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients. Ann Intern Med 2007; 146:278.</a></li><li><a class="nounderline abstract_t">Spyropoulos AC, Anderson FA Jr, Fitzgerald G, et al. Predictive and associative models to identify hospitalized medical patients at risk for VTE. Chest 2011; 140:706.</a></li><li><a class="nounderline abstract_t">Khouli H, Shapiro J, Pham VP, et al. Efficacy of deep venous thrombosis prophylaxis in the medical intensive care unit. J Intensive Care Med 2006; 21:352.</a></li><li><a class="nounderline abstract_t">Laporte S, Mismetti P. Epidemiology of thrombotic risk factors: the difficulty in using clinical trials to develop a risk assessment model. Crit Care Med 2010; 38:S10.</a></li><li><a class="nounderline abstract_t">Ortel TL. Acquired thrombotic risk factors in the critical care setting. Crit Care Med 2010; 38:S43.</a></li><li><a class="nounderline abstract_t">Wu C, Lee AY. Malignancy and venous thrombosis in the critical care patient. Crit Care Med 2010; 38:S64.</a></li><li><a class="nounderline abstract_t">Castellucci LA, Wells PS, Duffett L. Nonleg venous thrombosis in critically ill adults. JAMA 2015; 313:411.</a></li><li><a class="nounderline abstract_t">Lim W, Meade M, Lauzier F, et al. Failure of anticoagulant thromboprophylaxis: risk factors in medical-surgical critically ill patients*. Crit Care Med 2015; 43:401.</a></li><li><a class="nounderline abstract_t">Ho KM, Chavan S, Pilcher D. Omission of early thromboprophylaxis and mortality in critically ill patients: a multicenter registry study. Chest 2011; 140:1436.</a></li><li><a class="nounderline abstract_t">Gibson CD, Colvin MO, Park MJ, et al. Prevalence and Predictors of Deep Vein Thrombosis in Critically Ill Medical Patients Who Underwent Diagnostic Duplex Ultrasonography. J Intensive Care Med 2020; 35:1062.</a></li><li><a class="nounderline abstract_t">Sørensen HT, Horvath-Puho E, Søgaard KK, et al. Arterial cardiovascular events, statins, low-dose aspirin and subsequent risk of venous thromboembolism: a population-based case-control study. J Thromb Haemost 2009; 7:521.</a></li><li><a class="nounderline abstract_t">Glynn RJ, Danielson E, Fonseca FA, et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med 2009; 360:1851.</a></li><li><a class="nounderline abstract_t">Ramcharan AS, Van Stralen KJ, Snoep JD, et al. HMG-CoA reductase inhibitors, other lipid-lowering medication, antiplatelet therapy, and the risk of venous thrombosis. J Thromb Haemost 2009; 7:514.</a></li><li><a class="nounderline abstract_t">Rabinowich L, Steinvil A, Leshem-Rubinow E, et al. Adherence to statins is associated with reduced incidence of idiopathic venous thromboembolism: real-life data from a large healthcare maintenance organisation. Heart 2012; 98:1817.</a></li><li><a class="nounderline abstract_t">Ray JG, Mamdani M, Tsuyuki RT, et al. Use of statins and the subsequent development of deep vein thrombosis. Arch Intern Med 2001; 161:1405.</a></li><li><a class="nounderline abstract_t">Herrington DM, Vittinghoff E, Lin F, et al. Statin therapy, cardiovascular events, and total mortality in the Heart and Estrogen/Progestin Replacement Study (HERS). Circulation 2002; 105:2962.</a></li><li><a class="nounderline abstract_t">Lacut K, Oger E, Le Gal G, et al. Statins but not fibrates are associated with a reduced risk of venous thromboembolism: a hospital-based case-control study. Fundam Clin Pharmacol 2004; 18:477.</a></li><li><a class="nounderline abstract_t">Khemasuwan D, Divietro ML, Tangdhanakanond K, et al. Statins decrease the occurrence of venous thromboembolism in patients with cancer. Am J Med 2010; 123:60.</a></li><li><a class="nounderline abstract_t">Khemasuwan D, Chae YK, Gupta S, et al. Dose-related effect of statins in venous thrombosis risk reduction. Am J Med 2011; 124:852.</a></li><li><a class="nounderline abstract_t">Nguyen CD, Andersson C, Jensen TB, et al. Statin treatment and risk of recurrent venous thromboembolism: a nationwide cohort study. BMJ Open 2013; 3:e003135.</a></li><li><a class="nounderline abstract_t">Li L, Zhang P, Tian JH, Yang K. Statins for primary prevention of venous thromboembolism. Cochrane Database Syst Rev 2014; :CD008203.</a></li><li><a class="nounderline abstract_t">Kunutsor SK, Seidu S, Khunti K. Statins and secondary prevention of venous thromboembolism: pooled analysis of published observational cohort studies. Eur Heart J 2017; 38:1608.</a></li><li><a class="nounderline abstract_t">Rahimi K, Bhala N, Kamphuisen P, et al. Effect of statins on venous thromboembolic events: a meta-analysis of published and unpublished evidence from randomised controlled trials. PLoS Med 2012; 9:e1001310.</a></li><li><a class="nounderline abstract_t">Glynn RJ, Ridker PM, Goldhaber SZ, Buring JE. Effect of low-dose aspirin on the occurrence of venous thromboembolism: a randomized trial. Ann Intern Med 2007; 147:525.</a></li><li><a class="nounderline abstract_t">Hull RD, Hirsh J, Sackett DL, Stoddart GL. Cost-effectiveness of primary and secondary prevention of fatal pulmonary embolism in high-risk surgical patients. Can Med Assoc J 1982; 127:990.</a></li><li><a class="nounderline abstract_t">Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:381S.</a></li><li><a class="nounderline abstract_t">Meyer CS, Blebea J, Davis K Jr, et al. Surveillance venous scans for deep venous thrombosis in multiple trauma patients. Ann Vasc Surg 1995; 9:109.</a></li><li><a class="nounderline abstract_t">Schellong SM, Beyer J, Kakkar AK, et al. Ultrasound screening for asymptomatic deep vein thrombosis after major orthopaedic surgery: the VENUS study. J Thromb Haemost 2007; 5:1431.</a></li><li><a class="nounderline abstract_t">Kahn SR, Lim W, Dunn AS, et al. Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e195S.</a></li><li><a class="nounderline abstract_t">Nyquist P, Jichici D, Bautista C, et al. Prophylaxis of Venous Thrombosis in Neurocritical Care Patients: An Executive Summary of Evidence-Based Guidelines: A Statement for Healthcare Professionals From the Neurocritical Care Society and Society of Critical Care Medicine. Crit Care Med 2017; 45:476.</a></li><li><a class="nounderline abstract_t">Schünemann HJ, Cushman M, Burnett AE, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients. Blood Adv 2018; 2:3198.</a></li><li><a class="nounderline abstract_t">Neumann I, Izcovich A, Aguilar R, et al. American Society of Hematology, ABHH, ACHO, Grupo CAHT, Grupo CLAHT, SAH, SBHH, SHU, SOCHIHEM, SOMETH, Sociedad Panameña de Hematología, Sociedad Peruana de Hematología, and SVH 2022 guidelines for prevention of venous thromboembolism in surgical and medical patients and long-distance travelers in Latin America. Blood Adv 2022; 6:3636.</a></li><li><a class="nounderline abstract_t">Hill J, Treasure T, National Clinical Guideline Centre for Acute and Chronic Conditions. Reducing the risk of venous thromboembolism in patients admitted to hospital: summary of NICE guidance. BMJ 2010; 340:c95.</a></li><li><a class="nounderline abstract_t">Leizorovicz A, Cohen AT, Turpie AG, et al. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 2004; 110:874.</a></li><li><a class="nounderline abstract_t">Cohen AT, Davidson BL, Gallus AS, et al. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ 2006; 332:325.</a></li><li><a class="nounderline abstract_t">Alikhan R, Cohen AT. A safety analysis of thromboprophylaxis in acute medical illness. Thromb Haemost 2003; 89:590.</a></li><li><a class="nounderline abstract_t">Jois-Bilowich P, Michota F, Bartholomew JR, et al. Venous thromboembolism prophylaxis in hospitalized heart failure patients. J Card Fail 2008; 14:127.</a></li><li><a class="nounderline abstract_t">Wein L, Wein S, Haas SJ, et al. Pharmacological venous thromboembolism prophylaxis in hospitalized medical patients: a meta-analysis of randomized controlled trials. Arch Intern Med 2007; 167:1476.</a></li><li><a class="nounderline abstract_t">Själander A, Jansson JH, Bergqvist D, et al. Efficacy and safety of anticoagulant prophylaxis to prevent venous thromboembolism in acutely ill medical inpatients: a meta-analysis. J Intern Med 2008; 263:52.</a></li><li><a class="nounderline abstract_t">Lentine KL, Flavin KE, Gould MK. Variability in the use of thromboprophylaxis and outcomes in critically ill medical patients. Am J Med 2005; 118:1373.</a></li><li><a class="nounderline abstract_t">Kanaan AO, Silva MA, Donovan JL, et al. Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients. Clin Ther 2007; 29:2395.</a></li><li><a class="nounderline abstract_t">Dunn AS, Brenner A, Halm EA. The magnitude of an iatrogenic disorder: a systematic review of the incidence of venous thromboembolism for general medical inpatients. Thromb Haemost 2006; 95:758.</a></li><li><a class="nounderline abstract_t">Sherman DG, Albers GW, Bladin C, et al. The efficacy and safety of enoxaparin versus unfractionated heparin for the prevention of venous thromboembolism after acute ischaemic stroke (PREVAIL Study): an open-label randomised comparison. Lancet 2007; 369:1347.</a></li><li><a class="nounderline abstract_t">Bergmann JF, Neuhart E. A multicenter randomized double-blind study of enoxaparin compared with unfractionated heparin in the prevention of venous thromboembolic disease in elderly in-patients bedridden for an acute medical illness. The Enoxaparin in Medicine Study Group. Thromb Haemost 1996; 76:529.</a></li><li><a class="nounderline abstract_t">Ananthakrishnan AN, Cagan A, Gainer VS, et al. Thromboprophylaxis is associated with reduced post-hospitalization venous thromboembolic events in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol 2014; 12:1905.</a></li><li><a class="nounderline abstract_t">Cohen AT, Spiro TE, Spyropoulos AC, et al. D-dimer as a predictor of venous thromboembolism in acutely ill, hospitalized patients: a subanalysis of the randomized controlled MAGELLAN trial. J Thromb Haemost 2014; 12:479.</a></li><li><a class="nounderline abstract_t">Spyropoulos AC, McGinn T, Khorana AA. The use of weighted and scored risk assessment models for venous thromboembolism. Thromb Haemost 2012; 108:1072.</a></li><li><a class="nounderline abstract_t">Greene MT, Spyropoulos AC, Chopra V, et al. Validation of Risk Assessment Models of Venous Thromboembolism in Hospitalized Medical Patients. Am J Med 2016; 129:1001.e9.</a></li><li><a class="nounderline abstract_t">Kucher N, Koo S, Quiroz R, et al. Electronic alerts to prevent venous thromboembolism among hospitalized patients. N Engl J Med 2005; 352:969.</a></li><li><a class="nounderline abstract_t">Barbar S, Noventa F, Rossetto V, et al. A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score. J Thromb Haemost 2010; 8:2450.</a></li><li><a class="nounderline abstract_t">Spyropoulos AC, Lipardi C, Xu J, et al. Modified IMPROVE VTE Risk Score and Elevated D-Dimer Identify a High Venous Thromboembolism Risk in Acutely Ill Medical Population for Extended Thromboprophylaxis. TH Open 2020; 4:e59.</a></li><li><a class="nounderline abstract_t">Gibson CM, Spyropoulos AC, Cohen AT, et al. The IMPROVEDD VTE Risk Score: Incorporation of D-Dimer into the IMPROVE Score to Improve Venous Thromboembolism Risk Stratification. TH Open 2017; 1:e56.</a></li><li><a class="nounderline abstract_t">Nendaz M, Spirk D, Kucher N, et al. Multicentre validation of the Geneva Risk Score for hospitalised medical patients at risk of venous thromboembolism. Explicit ASsessment of Thromboembolic RIsk and Prophylaxis for Medical PATients in SwitzErland (ESTIMATE). Thromb Haemost 2014; 111:531.</a></li><li><a class="nounderline abstract_t">Decousus H, Tapson VF, Bergmann JF, et al. Factors at admission associated with bleeding risk in medical patients: findings from the IMPROVE investigators. Chest 2011; 139:69.</a></li><li><a class="nounderline abstract_t">Lauzier F, Arnold DM, Rabbat C, et al. Risk factors and impact of major bleeding in critically ill patients receiving heparin thromboprophylaxis. Intensive Care Med 2013; 39:2135.</a></li><li><a class="nounderline abstract_t">Sharma A, Chatterjee S, Lichstein E, Mukherjee D. Extended thromboprophylaxis for medically ill patients with decreased mobility: does it improve outcomes? J Thromb Haemost 2012; 10:2053.</a></li><li><a class="nounderline abstract_t">Cohen AT, Harrington RA, Goldhaber SZ, et al. Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients. N Engl J Med 2016; 375:534.</a></li><li><a class="nounderline abstract_t">Liew AY, Piran S, Eikelboom JW, Douketis JD. Extended-duration versus short-duration pharmacological thromboprophylaxis in acutely Ill hospitalized medical patients: a systematic review and meta-analysis of randomized controlled trials. J Thromb Thrombolysis 2017; 43:291.</a></li><li><a class="nounderline abstract_t">Zayed Y, Kheiri B, Barbarawi M, et al. Extended duration of thromboprophylaxis for medically ill patients: a systematic review and meta-analysis of randomised controlled trials. Intern Med J 2020; 50:192.</a></li><li><a class="nounderline abstract_t">Yusen RD, Hull RD, Schellong SM, et al. Impact of age on the efficacy and safety of extended-duration thromboprophylaxis in medical patients. Subgroup analysis from the EXCLAIM randomised trial. Thromb Haemost 2013; 110:1152.</a></li><li><a class="nounderline abstract_t">Goldhaber SZ, Leizorovicz A, Kakkar AK, et al. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med 2011; 365:2167.</a></li><li><a class="nounderline abstract_t">Cohen AT, Spiro TE, Büller HR, et al. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med 2013; 368:513.</a></li><li><a class="nounderline abstract_t">Bajaj NS, Vaduganathan M, Qamar A, et al. Extended prophylaxis for venous thromboembolism after hospitalization for medical illness: A trial sequential and cumulative meta-analysis. PLoS Med 2019; 16:e1002797.</a></li><li><a class="nounderline abstract_t">Gibson CM, Halaby R, Korjian S, et al. The safety and efficacy of full- versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention With Extended-Duration Betrixaban (APEX) trial. Am Heart J 2017; 185:93.</a></li><li><a class="nounderline abstract_t">Spyropoulos AC, Ageno W, Albers GW, et al. Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness. N Engl J Med 2018; 379:1118.</a></li><li><a class="nounderline abstract_t">Weitz JI, Raskob GE, Spyropoulos AC, et al. Thromboprophylaxis with Rivaroxaban in Acutely Ill Medical Patients with Renal Impairment: Insights from the MAGELLAN and MARINER Trials. Thromb Haemost 2020; 120:515.</a></li><li><a class="nounderline abstract_t">Jamil A, Jamil U, Singh K, et al. Extended Thromboprophylaxis With Betrixaban or Rivaroxaban for Acutely Ill Hospitalized Medical Patients: Meta-Analysis of Prespecified Subgroups. Crit Pathw Cardiol 2021; 20:16.</a></li><li><a class="nounderline abstract_t">Spyropoulos AC, Mahan C. Venous thromboembolism prophylaxis in the medical patient: controversies and perspectives. Am J Med 2009; 122:1077.</a></li><li><a class="nounderline abstract_t">Mismetti P, Laporte-Simitsidis S, Tardy B, et al. Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular-weight heparins: a meta-analysis of randomised clinical trials. Thromb Haemost 2000; 83:14.</a></li><li><a class="nounderline abstract_t">Hull RD, Schellong SM, Tapson VF, et al. Extended-duration thromboprophylaxis in acutely ill medical patients with recent reduced mobility: methodology for the EXCLAIM study. J Thromb Thrombolysis 2006; 22:31.</a></li><li><a class="nounderline abstract_t">Bump GM, Dandu M, Kaufman SR, et al. How complete is the evidence for thromboembolism prophylaxis in general medicine patients? A meta-analysis of randomized controlled trials. J Hosp Med 2009; 4:289.</a></li><li><a class="nounderline abstract_t">McGarry LJ, Stokes ME, Thompson D. Outcomes of thromboprophylaxis with enoxaparin vs. unfractionated heparin in medical inpatients. Thromb J 2006; 4:17.</a></li><li><a class="nounderline abstract_t">Laporte S, Liotier J, Bertoletti L, et al. Individual patient data meta-analysis of enoxaparin vs. unfractionated heparin for venous thromboembolism prevention in medical patients. J Thromb Haemost 2011; 9:464.</a></li><li><a class="nounderline abstract_t">Greig MF, Rochow SB, Crilly MA, Mangoni AA. Routine pharmacological venous thromboembolism prophylaxis in frail older hospitalised patients: where is the evidence? Age Ageing 2013; 42:428.</a></li><li><a class="nounderline abstract_t">Alikhan R, Bedenis R, Cohen AT. Heparin for the prevention of venous thromboembolism in acutely ill medical patients (excluding stroke and myocardial infarction). Cochrane Database Syst Rev 2014; :CD003747.</a></li><li><a class="nounderline abstract_t">Lilly CM, Liu X, Badawi O, et al. Thrombosis prophylaxis and mortality risk among critically ill adults. Chest 2014; 146:51.</a></li><li><a class="nounderline abstract_t">Eck RJ, Elling T, Sutton AJ, et al. Anticoagulants for thrombosis prophylaxis in acutely ill patients admitted to hospital: systematic review and network meta-analysis. BMJ 2022; 378:e070022.</a></li><li class="breakAll">Surgical Care Improvement Project (SCIP) http://www.jointcommission.org/surgical_care_improvement_project/ (Accessed on May 02, 2011).</li><li><a class="nounderline abstract_t">Diener HC, Ringelstein EB, von Kummer R, et al. Prophylaxis of thrombotic and embolic events in acute ischemic stroke with the low-molecular-weight heparin certoparin: results of the PROTECT Trial. Stroke 2006; 37:139.</a></li><li><a class="nounderline abstract_t">Shorr AF, Jackson WL, Sherner JH, Moores LK. Differences between low-molecular-weight and unfractionated heparin for venous thromboembolism prevention following ischemic stroke: a metaanalysis. Chest 2008; 133:149.</a></li><li><a class="nounderline abstract_t">Alhazzani W, Lim W, Jaeschke RZ, et al. Heparin thromboprophylaxis in medical-surgical critically ill patients: a systematic review and meta-analysis of randomized trials. Crit Care Med 2013; 41:2088.</a></li><li><a class="nounderline abstract_t">PROTECT Investigators for the Canadian Critical Care Trials Group and the Australian and New Zealand Intensive Care Society Clinical Trials Group, Cook D, Meade M, et al. Dalteparin versus unfractionated heparin in critically ill patients. N Engl J Med 2011; 364:1305.</a></li><li><a class="nounderline abstract_t">Beitland S, Sandven I, Kjærvik LK, et al. Thromboprophylaxis with low molecular weight heparin versus unfractionated heparin in intensive care patients: a systematic review with meta-analysis and trial sequential analysis. Intensive Care Med 2015; 41:1209.</a></li><li><a class="nounderline abstract_t">Fowler RA, Mittmann N, Geerts W, et al. Cost-effectiveness of dalteparin vs unfractionated heparin for the prevention of venous thromboembolism in critically ill patients. JAMA 2014; 312:2135.</a></li><li><a class="nounderline abstract_t">Fernando SM, Tran A, Cheng W, et al. VTE Prophylaxis in Critically Ill Adults: A Systematic Review and Network Meta-analysis. Chest 2022; 161:418.</a></li><li><a class="nounderline abstract_t">King CS, Holley AB, Jackson JL, et al. Twice vs three times daily heparin dosing for thromboembolism prophylaxis in the general medical population: A metaanalysis. Chest 2007; 131:507.</a></li><li><a class="nounderline abstract_t">Phung OJ, Kahn SR, Cook DJ, Murad MH. Dosing frequency of unfractionated heparin thromboprophylaxis: a meta-analysis. Chest 2011; 140:374.</a></li><li><a class="nounderline abstract_t">Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332:1330.</a></li><li><a class="nounderline abstract_t">Martel N, Lee J, Wells PS. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood 2005; 106:2710.</a></li><li><a class="nounderline abstract_t">Garcia DA, Baglin TP, Weitz JI, et al. Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e24S.</a></li><li><a class="nounderline abstract_t">Ageno W, Riva N, Noris P, et al. Safety and efficacy of low-dose fondaparinux (1.5 mg) for the prevention of venous thromboembolism in acutely ill medical patients with renal impairment: the FONDAIR study. J Thromb Haemost 2012; 10:2291.</a></li><li><a class="nounderline abstract_t">Collins R, Baigent C, Sandercock P, Peto R. Antiplatelet therapy for thromboprophylaxis: the need for careful consideration of the evidence from randomised trials. Antiplatelet Trialists' Collaboration. BMJ 1994; 309:1215.</a></li><li><a class="nounderline abstract_t">Karthikeyan G, Eikelboom JW, Turpie AG, Hirsh J. Does acetyl salicylic acid (ASA) have a role in the prevention of venous thromboembolism? Br J Haematol 2009; 146:142.</a></li><li class="breakAll">Betrixaban capsules. United States Prescribing Information. US National Library of Medicine. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208383s000lbl.pdf (Accessed on June 26, 2017).</li><li class="breakAll">Rivaroxaban tablets. United States Prescribing Information. US National Library of Medicine. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022406s033,202439s033lbl.pdf (Accessed on October 22, 2019).</li><li><a class="nounderline abstract_t">Raskob GE, van Es N, Verhamme P, et al. Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. N Engl J Med 2018; 378:615.</a></li><li><a class="nounderline abstract_t">Martin KA, Beyer-Westendorf J, Davidson BL, et al. Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: Updated communication from the ISTH SSC Subcommittee on Control of Anticoagulation. J Thromb Haemost 2021; 19:1874.</a></li><li><a class="nounderline abstract_t">Hajibandeh S, Hajibandeh S, Antoniou GA, et al. Neuromuscular electrical stimulation for the prevention of venous thromboembolism. Cochrane Database Syst Rev 2017; 11:CD011764.</a></li><li><a class="nounderline abstract_t">Roberts VC, Sabri S, Beeley AH, Cotton LT. The effect of intermittently applied external pressure on the haemodynamics of the lower limb in man. Br J Surg 1972; 59:223.</a></li><li><a class="nounderline abstract_t">Comerota AJ, Chouhan V, Harada RN, et al. The fibrinolytic effects of intermittent pneumatic compression: mechanism of enhanced fibrinolysis. Ann Surg 1997; 226:306.</a></li><li><a class="nounderline abstract_t">CLOTS (Clots in Legs Or sTockings after Stroke) Trials Collaboration, Dennis M, Sandercock P, et al. Effectiveness of intermittent pneumatic compression in reduction of risk of deep vein thrombosis in patients who have had a stroke (CLOTS 3): a multicentre randomised controlled trial. Lancet 2013; 382:516.</a></li><li><a class="nounderline abstract_t">André C, de Freitas GR, Fukujima MM. Prevention of deep venous thrombosis and pulmonary embolism following stroke: a systematic review of published articles. Eur J Neurol 2007; 14:21.</a></li><li><a class="nounderline abstract_t">CLOTS Trials Collaboration, Dennis M, Sandercock PA, et al. Effectiveness of thigh-length graduated compression stockings to reduce the risk of deep vein thrombosis after stroke (CLOTS trial 1): a multicentre, randomised controlled trial. Lancet 2009; 373:1958.</a></li><li><a class="nounderline abstract_t">Pour AE, Keshavarzi NR, Purtill JJ, et al. Is venous foot pump effective in prevention of thromboembolic disease after joint arthroplasty: a meta-analysis. J Arthroplasty 2013; 28:410.</a></li><li><a class="nounderline abstract_t">Corley GJ, Broderick BJ, Nestor SM, et al. The anatomy and physiology of the venous foot pump. Anat Rec (Hoboken) 2010; 293:370.</a></li><li><a class="nounderline abstract_t">Arabi YM, Al-Hameed F, Burns KEA, et al. Adjunctive Intermittent Pneumatic Compression for Venous Thromboprophylaxis. N Engl J Med 2019; 380:1305.</a></li><li class="breakAll">Shojania KG, Duncan BW, McDonald KM, et al. Making health care safer: a critical analysis of patient safety practices. Report/Technology Assessment No. 43. Rockville, MD: Agency for Healthcare Research and Quality. Available at: www.ahrq.gov/clinic/pt-safety/ (Accessed on January 03, 2002).</li><li class="breakAll">Specifications Manual for National Hospital Inpatient Quality Measures www.qualitynet.org (Accessed on March 11, 2009).</li><li class="breakAll">National Voluntary Consensus Standards for Prevention and Care of Venous Thromboembolism: Policy, preferred practices, and performance measures. http://www.qualityforum.org/Projects/s-z/VTE_Phase_I/Venous_Thromboembolism_(VTE)_I.aspx (Accessed on May 02, 2011).</li><li class="breakAll">U.S. Department of Health and Human Services and Joint Commission on Accreditation of Health Care Organizations http://www.hhs.gov/ and http://www.jointcommission.org/ (Accessed on May 02, 2011).</li><li><a class="nounderline abstract_t">Rathbun S. Cardiology patient pages. The Surgeon General's call to action to prevent deep vein thrombosis and pulmonary embolism. Circulation 2009; 119:e480.</a></li><li class="breakAll">Safer Healthcare Now www.saferhealthcarenow.ca (Accessed on May 02, 2011).</li><li class="breakAll">National Institute for Health and Clinical Excellence. Reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in patients admitted to hospital. NICE clinical guideline. http://www.nice.org.uk/CG092 (Accessed on June 09, 2010).</li><li><a class="nounderline abstract_t">Kucher N, Tapson VF, Goldhaber SZ, DVT FREE Steering Committee. Risk factors associated with symptomatic pulmonary embolism in a large cohort of deep vein thrombosis patients. Thromb Haemost 2005; 93:494.</a></li><li><a class="nounderline abstract_t">Cohen AT, Tapson VF, Bergmann JF, et al. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet 2008; 371:387.</a></li><li><a class="nounderline abstract_t">Kucher N, Leizorovicz A, Vaitkus PT, et al. Efficacy and safety of fixed low-dose dalteparin in preventing venous thromboembolism among obese or elderly hospitalized patients: a subgroup analysis of the PREVENT trial. Arch Intern Med 2005; 165:341.</a></li><li><a class="nounderline abstract_t">Rahme E, Dasgupta K, Burman M, et al. Postdischarge thromboprophylaxis and mortality risk after hip-or knee-replacement surgery. CMAJ 2008; 178:1545.</a></li><li><a class="nounderline abstract_t">Kahn SR, Panju A, Geerts W, et al. Multicenter evaluation of the use of venous thromboembolism prophylaxis in acutely ill medical patients in Canada. Thromb Res 2007; 119:145.</a></li><li><a class="nounderline abstract_t">Tapson VF, Hyers TM, Waldo AL, et al. Antithrombotic therapy practices in US hospitals in an era of practice guidelines. Arch Intern Med 2005; 165:1458.</a></li><li><a class="nounderline abstract_t">Cohn SL. Prophylaxis of venous thromboembolism in the US: improving hospital performance. J Thromb Haemost 2009; 7:1437.</a></li><li><a class="nounderline abstract_t">Bergmann JF, Cohen AT, Tapson VF, et al. Venous thromboembolism risk and prophylaxis in hospitalised medically ill patients. The ENDORSE Global Survey. Thromb Haemost 2010; 103:736.</a></li><li><a class="nounderline abstract_t">Mokhtari M, Salameh P, Kouchek M, et al. The AVAIL ME Extension: a multinational Middle Eastern survey of venous thromboembolism risk and prophylaxis. J Thromb Haemost 2011; 9:1340.</a></li><li><a class="nounderline abstract_t">Pendergraft T, Liu X, Edelsberg J, et al. Prophylaxis against venous thromboembolism in hospitalized medically ill patients. Circ Cardiovasc Qual Outcomes 2013; 6:75.</a></li><li><a class="nounderline abstract_t">Mahan CE, Spyropoulos AC. Venous thromboembolism prevention: a systematic review of methods to improve prophylaxis and decrease events in the hospitalized patient. Hosp Pract (1995) 2010; 38:97.</a></li><li><a class="nounderline abstract_t">Roberts LN, Porter G, Barker RD, et al. Comprehensive VTE prevention program incorporating mandatory risk assessment reduces the incidence of hospital-associated thrombosis. Chest 2013; 144:1276.</a></li><li><a class="nounderline abstract_t">Kahn SR, Morrison DR, Cohen JM, et al. Interventions for implementation of thromboprophylaxis in hospitalized medical and surgical patients at risk for venous thromboembolism. Cochrane Database Syst Rev 2013; :CD008201.</a></li><li><a class="nounderline abstract_t">Piazza G, Anderson FA, Ortel TL, et al. Randomized trial of physician alerts for thromboprophylaxis after discharge. Am J Med 2013; 126:435.</a></li><li><a class="nounderline abstract_t">Mahan CE, Liu Y, Turpie AG, et al. External validation of a risk assessment model for venous thromboembolism in the hospitalised acutely-ill medical patient (VTE-VALOURR). Thromb Haemost 2014; 112:692.</a></li><li><a class="nounderline abstract_t">Spyropolous AC, Goldin M, Koulas I, et al. Universal EHRs Clinical Decision Support for Thromboprophylaxis in Medical Inpatients. J Am Coll Cardiol 2023; 2.</a></li><li><a class="nounderline abstract_t">Bagot C, Gohil S, Perrott R, et al. The use of an exclusion-based risk-assessment model for venous thrombosis improves uptake of appropriate thromboprophylaxis in hospitalized medical patients. QJM 2010; 103:597.</a></li><li><a class="nounderline abstract_t">Lawall H, Matthiessen A, Hohmann V, et al. Venous thromboembolism in medical outpatients - a cross-sectional survey of risk assessment and prophylaxis. Thromb Haemost 2011; 105:190.</a></li><li><a class="nounderline abstract_t">Tooher R, Middleton P, Pham C, et al. A systematic review of strategies to improve prophylaxis for venous thromboembolism in hospitals. Ann Surg 2005; 241:397.</a></li><li><a class="nounderline abstract_t">Stinnett JM, Pendleton R, Skordos L, et al. Venous thromboembolism prophylaxis in medically ill patients and the development of strategies to improve prophylaxis rates. Am J Hematol 2005; 78:167.</a></li><li><a class="nounderline abstract_t">Schünemann HJ, Cook D, Grimshaw J, et al. Antithrombotic and thrombolytic therapy: from evidence to application: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126:688S.</a></li><li><a class="nounderline abstract_t">Yu HT, Dylan ML, Lin J, Dubois RW. Hospitals' compliance with prophylaxis guidelines for venous thromboembolism. Am J Health Syst Pharm 2007; 64:69.</a></li><li><a class="nounderline abstract_t">Piazza G, Rosenbaum EJ, Pendergast W, et al. Physician alerts to prevent symptomatic venous thromboembolism in hospitalized patients. Circulation 2009; 119:2196.</a></li><li><a class="nounderline abstract_t">Piazza G, Goldhaber SZ. Computerized decision support for the cardiovascular clinician: applications for venous thromboembolism prevention and beyond. Circulation 2009; 120:1133.</a></li><li><a class="nounderline abstract_t">Kucher N, Puck M, Blaser J, et al. Physician compliance with advanced electronic alerts for preventing venous thromboembolism among hospitalized medical patients. J Thromb Haemost 2009; 7:1291.</a></li><li><a class="nounderline abstract_t">Piazza G, Fanikos J, Zayaruzny M, Goldhaber SZ. Venous thromboembolic events in hospitalised medical patients. Thromb Haemost 2009; 102:505.</a></li><li><a class="nounderline abstract_t">Fanikos J, Piazza G, Zayaruzny M, Goldhaber SZ. Long-term complications of medical patients with hospital-acquired venous thromboembolism. Thromb Haemost 2009; 102:688.</a></li><li><a class="nounderline abstract_t">Baglin T. Defining the population in need of thromboprophylaxis - making hospitals safer. Br J Haematol 2010; 149:805.</a></li></ol></div><div id="topicVersionRevision">Topic 1346 Version 109.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17626254" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Estimated annual numbers of US acute-care hospital patients at risk for venous thromboembolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1873716" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Autopsy-verified pulmonary embolism in a surgical department: analysis of the period from 1951 to 1988.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7555172" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Prevalence of acute pulmonary embolism among patients in a general hospital and at autopsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12958614" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Incidence of symptomatic venous thromboembolism after different elective or urgent surgical procedures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2716016" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Autopsy proven pulmonary embolism in hospital patients: are we detecting enough deep vein thrombosis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16507939" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Pulmonary embolism after major abdominal surgery in gynecologic oncology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3959287" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Pulmonary embolism as a cause of death. The changing mortality in hospitalized patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12885687" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Pulmonary embolism mortality in the United States, 1979-1998: an analysis using multiple-cause mortality data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22705598" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : How I manage venous thromboembolism risk in hospitalized medical patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12038942" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18422787" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Risk stratification and venous thromboprophylaxis in hospitalized medical and cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11449339" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Effective risk stratification of surgical and nonsurgical patients for venous thromboembolic disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17264013" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Risk factors and clinical impact of postoperative symptomatic venous thromboembolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17164492" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : An evaluation of venous thromboembolic risk in acutely ill medical patients immobilized at home: the AT-HOME Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12814980" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Risk factors for venous thromboembolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11112234" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19106028" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Risk factors for perioperative mortality after lower extremity arthroplasty: a population-based study of 6,901,324 patient discharges.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16270626" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Assessment of venous thromboembolism risk and the benefits of thromboprophylaxis in medical patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16634771" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Identifying acutely ill medical patients requiring thromboprophylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15613021" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Risk factors for venous thrombosis in medical inpatients: validation of a thrombosis risk score.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16003063" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Deep venous thrombosis in medical-surgical critically ill patients: prevalence, incidence, and risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14687996" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Quantification of risk factors for venous thromboembolism: a preliminary study for the development of a risk assessment tool.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18841419" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Venous thromboembolism in cancer patients undergoing major surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10407692" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Risk factors for venous thromboembolism in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9240601" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Changes in activated protein C resistance during normal pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11702898" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Incidence of venous thromboembolism in hospitalized patients vs community residents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3283548" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopedic, and urologic surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/49649" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Prevention of fatal postoperative pulmonary embolism by low doses of heparin. An international multicentre trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10477777" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20621900" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7073148" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Reduction of mortality in general medical in-patients by low-dose heparin prophylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8637340" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Randomised, controlled trial of low-dose heparin for prevention of fatal pulmonary embolism in patients with infectious diseases. The Heparin Prophylaxis Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15981008" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Lack of effect of a low-molecular-weight heparin (nadroparin) on mortality in bedridden medical in-patients: a prospective randomised double-blind study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22204723" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Low-molecular-weight heparin and mortality in acutely ill medical patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22041949" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Venous thromboembolism prophylaxis in hospitalized medical patients and those with stroke: a background review for an American College of Physicians Clinical Practice Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24038168" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Fatal venous thromboembolism associated with hospital admission: a cohort study to assess the impact of a national risk assessment target.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28483763" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Effect of a near-universal hospitalization-based prophylaxis regimen on annual number of venous thromboembolism events in the US.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17310052" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Meta-analysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21436241" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Predictive and associative models to identify hospitalized medical patients at risk for VTE.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17095499" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Efficacy of deep venous thrombosis prophylaxis in the medical intensive care unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20083908" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Epidemiology of thrombotic risk factors: the difficulty in using clinical trials to develop a risk assessment model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20083913" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Acquired thrombotic risk factors in the critical care setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20083916" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Malignancy and venous thrombosis in the critical care patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25626038" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Nonleg venous thrombosis in critically ill adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25474533" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Failure of anticoagulant thromboprophylaxis: risk factors in medical-surgical critically ill patients*.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21940768" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Omission of early thromboprophylaxis and mortality in critically ill patients: a multicenter registry study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30453801" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Prevalence and Predictors of Deep Vein Thrombosis in Critically Ill Medical Patients Who Underwent Diagnostic Duplex Ultrasonography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19192118" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Arterial cardiovascular events, statins, low-dose aspirin and subsequent risk of venous thromboembolism: a population-based case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19329822" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : A randomized trial of rosuvastatin in the prevention of venous thromboembolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19036068" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : HMG-CoA reductase inhibitors, other lipid-lowering medication, antiplatelet therapy, and the risk of venous thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23038788" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Adherence to statins is associated with reduced incidence of idiopathic venous thromboembolism: real-life data from a large healthcare maintenance organisation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11386889" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Use of statins and the subsequent development of deep vein thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12081988" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Statin therapy, cardiovascular events, and total mortality in the Heart and Estrogen/Progestin Replacement Study (HERS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15312155" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Statins but not fibrates are associated with a reduced risk of venous thromboembolism: a hospital-based case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20102993" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Statins decrease the occurrence of venous thromboembolism in patients with cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21783169" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Dose-related effect of statins in venous thrombosis risk reduction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24202053" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Statin treatment and risk of recurrent venous thromboembolism: a nationwide cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25518837" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Statins for primary prevention of venous thromboembolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28369602" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Statins and secondary prevention of venous thromboembolism: pooled analysis of published observational cohort studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23028261" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Effect of statins on venous thromboembolic events: a meta-analysis of published and unpublished evidence from randomised controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17938390" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Effect of low-dose aspirin on the occurrence of venous thromboembolism: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6182968" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Cost-effectiveness of primary and secondary prevention of fatal pulmonary embolism in high-risk surgical patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18574271" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7703054" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Surveillance venous scans for deep venous thrombosis in multiple trauma patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17419763" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Ultrasound screening for asymptomatic deep vein thrombosis after major orthopaedic surgery: the VENUS study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22315261" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28085682" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Prophylaxis of Venous Thrombosis in Neurocritical Care Patients: An Executive Summary of Evidence-Based Guidelines: A Statement for Healthcare Professionals From the Neurocritical Care Society and Society of Critical Care Medicine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30482763" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35195676" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : American Society of Hematology, ABHH, ACHO, Grupo CAHT, Grupo CLAHT, SAH, SBHH, SHU, SOCHIHEM, SOMETH, Sociedad Panameña de Hematología, Sociedad Peruana de Hematología, and SVH 2022 guidelines for prevention of venous thromboembolism in surgical and medical patients and long-distance travelers in Latin America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20106897" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Reducing the risk of venous thromboembolism in patients admitted to hospital: summary of NICE guidance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15289368" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16439370" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12624645" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : A safety analysis of thromboprophylaxis in acute medical illness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18325459" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Venous thromboembolism prophylaxis in hospitalized heart failure patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17646601" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Pharmacological venous thromboembolism prophylaxis in hospitalized medical patients: a meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18088252" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Efficacy and safety of anticoagulant prophylaxis to prevent venous thromboembolism in acutely ill medical inpatients: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16378781" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Variability in the use of thromboprophylaxis and outcomes in critically ill medical patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18158080" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16676063" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : The magnitude of an iatrogenic disorder: a systematic review of the incidence of venous thromboembolism for general medical inpatients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17448820" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : The efficacy and safety of enoxaparin versus unfractionated heparin for the prevention of venous thromboembolism after acute ischaemic stroke (PREVAIL Study): an open-label randomised comparison.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8902991" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : A multicenter randomized double-blind study of enoxaparin compared with unfractionated heparin in the prevention of venous thromboembolic disease in elderly in-patients bedridden for an acute medical illness. The Enoxaparin in Medicine Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24632349" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Thromboprophylaxis is associated with reduced post-hospitalization venous thromboembolic events in patients with inflammatory bowel diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24460645" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : D-dimer as a predictor of venous thromboembolism in acutely ill, hospitalized patients: a subanalysis of the randomized controlled MAGELLAN trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23138506" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : The use of weighted and scored risk assessment models for venous thromboembolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27107925" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Validation of Risk Assessment Models of Venous Thromboembolism in Hospitalized Medical Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15758007" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Electronic alerts to prevent venous thromboembolism among hospitalized patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20738765" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32190813" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Modified IMPROVE VTE Risk Score and Elevated D-Dimer Identify a High Venous Thromboembolism Risk in Acutely Ill Medical Population for Extended Thromboprophylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31249911" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : The IMPROVEDD VTE Risk Score: Incorporation of D-Dimer into the IMPROVE Score to Improve Venous Thromboembolism Risk Stratification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24226257" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Multicentre validation of the Geneva Risk Score for hospitalised medical patients at risk of venous thromboembolism. Explicit ASsessment of Thromboembolic RIsk and Prophylaxis for Medical PATients in SwitzErland (ESTIMATE).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20453069" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Factors at admission associated with bleeding risk in medical patients: findings from the IMPROVE investigators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23942857" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Risk factors and impact of major bleeding in critically ill patients receiving heparin thromboprophylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22863355" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Extended thromboprophylaxis for medically ill patients with decreased mobility: does it improve outcomes?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27232649" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27900627" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Extended-duration versus short-duration pharmacological thromboprophylaxis in acutely Ill hospitalized medical patients: a systematic review and meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31276276" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Extended duration of thromboprophylaxis for medically ill patients: a systematic review and meta-analysis of randomised controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24085227" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Impact of age on the efficacy and safety of extended-duration thromboprophylaxis in medical patients. Subgroup analysis from the EXCLAIM randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22077144" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23388003" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Rivaroxaban for thromboprophylaxis in acutely ill medical patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31034476" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Extended prophylaxis for venous thromboembolism after hospitalization for medical illness: A trial sequential and cumulative meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28267480" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : The safety and efficacy of full- versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention With Extended-Duration Betrixaban (APEX) trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30145946" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31975354" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Thromboprophylaxis with Rivaroxaban in Acutely Ill Medical Patients with Renal Impairment: Insights from the MAGELLAN and MARINER Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32657973" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Extended Thromboprophylaxis With Betrixaban or Rivaroxaban for Acutely Ill Hospitalized Medical Patients: Meta-Analysis of Prespecified Subgroups.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19958882" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Venous thromboembolism prophylaxis in the medical patient: controversies and perspectives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10669147" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular-weight heparins: a meta-analysis of randomised clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16786230" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Extended-duration thromboprophylaxis in acutely ill medical patients with recent reduced mobility: methodology for the EXCLAIM study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19504490" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : How complete is the evidence for thromboembolism prophylaxis in general medicine patients? A meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17005045" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Outcomes of thromboprophylaxis with enoxaparin vs. unfractionated heparin in medical inpatients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21232002" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Individual patient data meta-analysis of enoxaparin vs. unfractionated heparin for venous thromboembolism prevention in medical patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23557678" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Routine pharmacological venous thromboembolism prophylaxis in frail older hospitalised patients: where is the evidence?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24804622" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Heparin for the prevention of venous thromboembolism in acutely ill medical patients (excluding stroke and myocardial infarction).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24722879" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Thrombosis prophylaxis and mortality risk among critically ill adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35788047" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Anticoagulants for thrombosis prophylaxis in acutely ill patients admitted to hospital: systematic review and network meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35788047" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Anticoagulants for thrombosis prophylaxis in acutely ill patients admitted to hospital: systematic review and network meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16306456" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Prophylaxis of thrombotic and embolic events in acute ischemic stroke with the low-molecular-weight heparin certoparin: results of the PROTECT Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17925410" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Differences between low-molecular-weight and unfractionated heparin for venous thromboembolism prevention following ischemic stroke: a metaanalysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23782973" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Heparin thromboprophylaxis in medical-surgical critically ill patients: a systematic review and meta-analysis of randomized trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21417952" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Dalteparin versus unfractionated heparin in critically ill patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25971389" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Thromboprophylaxis with low molecular weight heparin versus unfractionated heparin in intensive care patients: a systematic review with meta-analysis and trial sequential analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25362228" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Cost-effectiveness of dalteparin vs unfractionated heparin for the prevention of venous thromboembolism in critically ill patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34419428" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : VTE Prophylaxis in Critically Ill Adults: A Systematic Review and Network Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17296655" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Twice vs three times daily heparin dosing for thromboembolism prophylaxis in the general medical population: A metaanalysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21349929" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Dosing frequency of unfractionated heparin thromboprophylaxis: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7715641" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15985543" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22315264" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22925036" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Safety and efficacy of low-dose fondaparinux (1.5 mg) for the prevention of venous thromboembolism in acutely ill medical patients with renal impairment: the FONDAIR study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7987156" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Antiplatelet therapy for thromboprophylaxis: the need for careful consideration of the evidence from randomised trials. Antiplatelet Trialists' Collaboration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19438502" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Does acetyl salicylic acid (ASA) have a role in the prevention of venous thromboembolism?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19438502" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Does acetyl salicylic acid (ASA) have a role in the prevention of venous thromboembolism?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19438502" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Does acetyl salicylic acid (ASA) have a role in the prevention of venous thromboembolism?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29231094" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34259389" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: Updated communication from the ISTH SSC Subcommittee on Control of Anticoagulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29161465" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Neuromuscular electrical stimulation for the prevention of venous thromboembolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5014527" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : The effect of intermittently applied external pressure on the haemodynamics of the lower limb in man.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9339937" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : The fibrinolytic effects of intermittent pneumatic compression: mechanism of enhanced fibrinolysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23727163" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Effectiveness of intermittent pneumatic compression in reduction of risk of deep vein thrombosis in patients who have had a stroke (CLOTS 3): a multicentre randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17222109" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Prevention of deep venous thrombosis and pulmonary embolism following stroke: a systematic review of published articles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19477503" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Effectiveness of thigh-length graduated compression stockings to reduce the risk of deep vein thrombosis after stroke (CLOTS trial 1): a multicentre, randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23102505" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Is venous foot pump effective in prevention of thromboembolic disease after joint arthroplasty: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19957343" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : The anatomy and physiology of the venous foot pump.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30779530" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Adjunctive Intermittent Pneumatic Compression for Venous Thromboprophylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30779530" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Adjunctive Intermittent Pneumatic Compression for Venous Thromboprophylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30779530" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Adjunctive Intermittent Pneumatic Compression for Venous Thromboprophylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30779530" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : Adjunctive Intermittent Pneumatic Compression for Venous Thromboprophylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30779530" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Adjunctive Intermittent Pneumatic Compression for Venous Thromboprophylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19380627" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : Cardiology patient pages. The Surgeon General's call to action to prevent deep vein thrombosis and pulmonary embolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19380627" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : Cardiology patient pages. The Surgeon General's call to action to prevent deep vein thrombosis and pulmonary embolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19380627" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : Cardiology patient pages. The Surgeon General's call to action to prevent deep vein thrombosis and pulmonary embolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15735800" id="rid150" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>151 : Risk factors associated with symptomatic pulmonary embolism in a large cohort of deep vein thrombosis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18242412" id="rid151" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>152 : Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15710801" id="rid152" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>153 : Efficacy and safety of fixed low-dose dalteparin in preventing venous thromboembolism among obese or elderly hospitalized patients: a subgroup analysis of the PREVENT trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18519902" id="rid153" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>154 : Postdischarge thromboprophylaxis and mortality risk after hip-or knee-replacement surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16516275" id="rid154" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>155 : Multicenter evaluation of the use of venous thromboembolism prophylaxis in acutely ill medical patients in Canada.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16009860" id="rid155" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>156 : Antithrombotic therapy practices in US hospitals in an era of practice guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19566791" id="rid156" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>157 : Prophylaxis of venous thromboembolism in the US: improving hospital performance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20135072" id="rid157" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>158 : Venous thromboembolism risk and prophylaxis in hospitalised medically ill patients. The ENDORSE Global Survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21605327" id="rid158" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>159 : The AVAIL ME Extension: a multinational Middle Eastern survey of venous thromboembolism risk and prophylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23300270" id="rid159" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>160 : Prophylaxis against venous thromboembolism in hospitalized medically ill patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20469630" id="rid160" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>161 : Venous thromboembolism prevention: a systematic review of methods to improve prophylaxis and decrease events in the hospitalized patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23681495" id="rid161" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>162 : Comprehensive VTE prevention program incorporating mandatory risk assessment reduces the incidence of hospital-associated thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23861035" id="rid162" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>163 : Interventions for implementation of thromboprophylaxis in hospitalized medical and surgical patients at risk for venous thromboembolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23510945" id="rid163" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>164 : Randomized trial of physician alerts for thromboprophylaxis after discharge.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24990708" id="rid164" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>165 : External validation of a risk assessment model for venous thromboembolism in the hospitalised acutely-ill medical patient (VTE-VALOURR).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid165" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>166 : Universal EHRs Clinical Decision Support for Thromboprophylaxis in Medical Inpatients</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20621966" id="rid166" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>167 : The use of an exclusion-based risk-assessment model for venous thrombosis improves uptake of appropriate thromboprophylaxis in hospitalized medical patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20978716" id="rid167" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>168 : Venous thromboembolism in medical outpatients - a cross-sectional survey of risk assessment and prophylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15729062" id="rid168" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>169 : A systematic review of strategies to improve prophylaxis for venous thromboembolism in hospitals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15726600" id="rid169" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>170 : Venous thromboembolism prophylaxis in medically ill patients and the development of strategies to improve prophylaxis rates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15383490" id="rid170" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>171 : Antithrombotic and thrombolytic therapy: from evidence to application: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17189583" id="rid171" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>172 : Hospitals' compliance with prophylaxis guidelines for venous thromboembolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19364975" id="rid172" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>173 : Physician alerts to prevent symptomatic venous thromboembolism in hospitalized patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19770412" id="rid173" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>174 : Computerized decision support for the cardiovascular clinician: applications for venous thromboembolism prevention and beyond.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19522743" id="rid174" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>175 : Physician compliance with advanced electronic alerts for preventing venous thromboembolism among hospitalized medical patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19718471" id="rid175" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>176 : Venous thromboembolic events in hospitalised medical patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19806254" id="rid176" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>177 : Long-term complications of medical patients with hospital-acquired venous thromboembolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20433681" id="rid177" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>178 : Defining the population in need of thromboprophylaxis - making hospitals safer.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
